array:25 [
  "pii" => "S0001731021002027"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2021.05.010"
  "estado" => "S300"
  "fechaPublicacion" => "2021-10-01"
  "aid" => "2679"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2021;112:817-27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S1578219021002158"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2021.07.015"
      "estado" => "S300"
      "fechaPublicacion" => "2021-10-01"
      "aid" => "2679"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2021;112:817-27"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
        "titulo" => "Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain&#58; Results From the APPRECIATE Study"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "817"
            "paginaFinal" => "827"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Caracterizaci&#243;n y resultados de pacientes tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual espa&#241;ola&#58; resultados del estudio APPRECIATE"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0010"
            "etiqueta" => "Figure 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 1425
                "Ancho" => 2556
                "Tamanyo" => 179232
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0010"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Main reasons for considering apremilast treatment&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "P&#46; Herranz, L&#46; Trasobares, A&#46; Mateu, E&#46; Mart&#237;nez, R&#46; Ruiz-Villaverde, O&#46; Baniandr&#233;s, J&#46; Mataix D&#237;az, N&#46; Jim&#233;nez-G&#243;mez, M&#46; Serra, D&#46;P&#46; Ruiz Genao, N&#46; Rivera, J&#46; Tercedor-S&#225;nchez, C&#46; Garcia, M&#46; Cordey, E&#46; Herrera-Acosta"
            "autores" => array:15 [
              0 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz"
              ]
              1 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Trasobares"
              ]
              2 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Mateu"
              ]
              3 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Mart&#237;nez"
              ]
              4 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Ruiz-Villaverde"
              ]
              5 => array:2 [
                "nombre" => "O&#46;"
                "apellidos" => "Baniandr&#233;s"
              ]
              6 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Mataix D&#237;az"
              ]
              7 => array:2 [
                "nombre" => "N&#46;"
                "apellidos" => "Jim&#233;nez-G&#243;mez"
              ]
              8 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Serra"
              ]
              9 => array:2 [
                "nombre" => "D&#46;P&#46;"
                "apellidos" => "Ruiz Genao"
              ]
              10 => array:2 [
                "nombre" => "N&#46;"
                "apellidos" => "Rivera"
              ]
              11 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Tercedor-S&#225;nchez"
              ]
              12 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Garcia"
              ]
              13 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Cordey"
              ]
              14 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Herrera-Acosta"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731021002027"
          "doi" => "10.1016/j.ad.2021.05.010"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002027?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002158?idApp=UINPBA000044"
      "url" => "/15782190/0000011200000009/v1_202110091021/S1578219021002158/v1_202110091021/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S0001731021002039"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2021.05.011"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "2680"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "rev"
    "cita" => "Actas Dermosifiliogr. 2021;112:828-36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Novedades en Dermatolog&#237;a</span>"
      "titulo" => "Vacunas frente a SARS-CoV-2 y piel"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "828"
          "paginaFinal" => "836"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "SARS-CoV-2 Vaccines and the Skin"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0030"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 594
              "Ancho" => 1333
              "Tamanyo" => 113821
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Galv&#225;n-Casas, A&#46; Catal&#224;, C&#46; Mu&#241;oz-Santos"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Galv&#225;n-Casas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Catal&#224;"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Mu&#241;oz-Santos"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0030"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219021002407"
        "doi" => "10.1016/j.adengl.2021.07.028"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002407?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002039?idApp=UINPBA000044"
    "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021002039/v1_202110020514/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731021001988"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2021.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "2675"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2021;112:806-16"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
      "titulo" => "Descripci&#243;n basal de la cohorte nacional prospectiva de hemangiomas infantiles de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#46; Comparaci&#243;n de los pacientes tratados con propranolol en la pr&#225;ctica cl&#237;nica rutinaria y los datos del ensayo cl&#237;nico pivotal previo"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "806"
          "paginaFinal" => "816"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Baseline Description of the Spanish Academy of Dermatology Infantile Haemangioma Nationwide Prospective Cohort&#46; Comparison of Patients Treated with Propranolol in Routine Clinical Practice with Previous Pivotal Clinical Trial Data"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0005"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 1085
              "Ancho" => 1319
              "Tamanyo" => 102004
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Cuenca-Barrales, E&#46; Baselga-Torres, J&#46; del Boz-Gonz&#225;lez, A&#46; Vicente, S&#46;I&#46; Palencia-P&#233;rez, M&#46; Campos-Dom&#237;nguez, M&#46; Valdivieso-Ramos, A&#46; Mart&#237;n-Santiago, M&#46;T&#46; Monserrat-Garc&#237;a, A&#46; Az&#243;n-Masoliver, M&#46; Feito-Rodr&#237;guez, J&#46;J&#46; Dom&#237;nguez-Cruz, E&#46; Ro&#233;-Crespo, C&#46; Salas-M&#225;rquez, A&#46; Giacaman, A&#46;I&#46; Lorente-Lavirgen, L&#46; Quintana-Castanedo, M&#46; de Vega-Mart&#237;nez, I&#46; Garc&#237;a-Doval, J&#46; Bernab&#233;u-Wittel"
          "autores" => array:20 [
            0 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Cuenca-Barrales"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Baselga-Torres"
            ]
            2 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "del Boz-Gonz&#225;lez"
            ]
            3 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Vicente"
            ]
            4 => array:2 [
              "nombre" => "S&#46;I&#46;"
              "apellidos" => "Palencia-P&#233;rez"
            ]
            5 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Campos-Dom&#237;nguez"
            ]
            6 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Valdivieso-Ramos"
            ]
            7 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Mart&#237;n-Santiago"
            ]
            8 => array:2 [
              "nombre" => "M&#46;T&#46;"
              "apellidos" => "Monserrat-Garc&#237;a"
            ]
            9 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Az&#243;n-Masoliver"
            ]
            10 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Feito-Rodr&#237;guez"
            ]
            11 => array:2 [
              "nombre" => "J&#46;J&#46;"
              "apellidos" => "Dom&#237;nguez-Cruz"
            ]
            12 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Ro&#233;-Crespo"
            ]
            13 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Salas-M&#225;rquez"
            ]
            14 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Giacaman"
            ]
            15 => array:2 [
              "nombre" => "A&#46;I&#46;"
              "apellidos" => "Lorente-Lavirgen"
            ]
            16 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Quintana-Castanedo"
            ]
            17 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "de Vega-Mart&#237;nez"
            ]
            18 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Garc&#237;a-Doval"
            ]
            19 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Bernab&#233;u-Wittel"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219021002419"
        "doi" => "10.1016/j.adengl.2021.08.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002419?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001988?idApp=UINPBA000044"
    "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021001988/v1_202110020514/es/main.assets"
  ]
  "es" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
    "titulo" => "Caracterizaci&#243;n y resultados de pacientes tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual espa&#241;ola&#58; resultados del estudio APPRECIATE"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "817"
        "paginaFinal" => "827"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "P&#46; Herranz, L&#46; Trasobares, A&#46; Mateu, E&#46; Mart&#237;nez, R&#46; Ruiz-Villaverde, O&#46; Baniandr&#233;s, J&#46; Mataix D&#237;az, N&#46; Jim&#233;nez-G&#243;mez, M&#46; Serra, D&#46;P&#46; Ruiz Genao, N&#46; Rivera, J&#46; Tercedor-S&#225;nchez, C&#46; Garcia, M&#46; Cordey, E&#46; Herrera-Acosta"
        "autores" => array:15 [
          0 => array:4 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz"
            "email" => array:1 [
              0 => "pedro.herranz@salud.madrid.org"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Trasobares"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Mateu"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Mart&#237;nez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Ruiz-Villaverde"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "O&#46;"
            "apellidos" => "Baniandr&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Mataix D&#237;az"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "N&#46;"
            "apellidos" => "Jim&#233;nez-G&#243;mez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Serra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "D&#46;P&#46;"
            "apellidos" => "Ruiz Genao"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "N&#46;"
            "apellidos" => "Rivera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Tercedor-S&#225;nchez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">l</span>"
                "identificador" => "aff0060"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Garcia"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0065"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Cordey"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">n</span>"
                "identificador" => "aff0070"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Herrera-Acosta"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">o</span>"
                "identificador" => "aff0075"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:15 [
          0 => array:3 [
            "entidad" => "Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Hospital Universitario Pr&#237;ncipe de Asturias&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Hospital Universitario Doctor Peset&#44; Valencia&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Hospital Llu&#237;s Alcany&#237;s X&#224;tiva&#44; Valencia&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Hospital Cl&#237;nico Universitario San Cecilio&#44; Granada&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Hospital Marina Baixa&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Hospital Ramon y Cajal&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Hospital Can Misses&#44; Illes Balears&#44; Espa&#241;a"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Fundaci&#243;n Hospital Alcorc&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Hospital de Mollet&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
          11 => array:3 [
            "entidad" => "Hospital Universitario Virgen de las Nieves&#44; Granada&#44; Espa&#241;a"
            "etiqueta" => "l"
            "identificador" => "aff0060"
          ]
          12 => array:3 [
            "entidad" => "Amgen Inc&#46;&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "m"
            "identificador" => "aff0065"
          ]
          13 => array:3 [
            "entidad" => "Amgen Inc&#46;&#44; Amgen &#40;Europe&#41; GmbH&#44; Rotkreuz&#44; Suiza"
            "etiqueta" => "n"
            "identificador" => "aff0070"
          ]
          14 => array:3 [
            "entidad" => "Vithas Xanit Iinternational Hospital&#44; M&#225;laga&#44; Espa&#241;a"
            "etiqueta" => "o"
            "identificador" => "aff0075"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain&#58; Results From the APPRECIATE Study"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0030"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1075
            "Ancho" => 1333
            "Tamanyo" => 171831
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">El uso de apremilast &#40;inhibidor oral de la fosfodiesterasa 4&#41; fue aprobado en Europa para tratar la psoriasis cr&#243;nica en placas de moderada a grave y la artritis psori&#225;sica en 2015<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#46; A partir de ensayos cl&#237;nicos&#44; apremilast demostr&#243; su eficacia y seguridad en pacientes con psoriasis de moderada a grave previamente tratados con terapias sist&#233;micas &#40;ESTEEM 1 y 2&#41;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; sin terapia biol&#243;gica previa &#40;LIBERATE&#41;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> y sin terapia biol&#243;gica o sist&#233;mica previa &#40;UNVEIL&#41;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a>&#46; Posteriormente&#44; la efectividad mostrada en las series de pr&#225;ctica cl&#237;nica&#44; en perfiles de pacientes diferentes a los de los ensayos pivotales&#44; parece ser superior&#46; Por ello&#44; se consider&#243; conveniente ampliar el conocimiento sobre el uso y efectividad de apremilast en condiciones de pr&#225;ctica cl&#237;nica&#44; frente a los ensayos pivotales mencionados&#44; y generar datos sobre la satisfacci&#243;n obtenida por pacientes y dermat&#243;logos tras el uso de apremilast&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El estudio APPRECIATE &#40;NCT02740218&#41; tiene como objetivo describir las caracter&#237;sticas de los pacientes con psoriasis tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual y evaluar las perspectivas de los pacientes y dermat&#243;logos cuando se inicia el tratamiento&#44; junto con los resultados y beneficios cl&#237;nicos obtenidos&#46; Los resultados de Alemania&#44; Austria&#44; Irlanda&#44; Reino Unido&#44; Suecia y Suiza fueron publicados recientemente<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a>&#46; En el presente trabajo se presentan los resultados de Espa&#241;a&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">M&#233;todos</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Dise&#241;o del estudio</span><p id="par0015" class="elsevierStylePara elsevierViewall">APPRECIATE es un estudio observacional&#44; retrospectivo&#44; transversal e internacional&#44; que recoge los resultados con apremilast seis meses despu&#233;s de iniciar tratamiento en la pr&#225;ctica cl&#237;nica habitual &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; El presente an&#225;lisis incluy&#243; los datos recopilados en 13 hospitales de Espa&#241;a&#44; donde el reclutamiento de pacientes se inici&#243; en mayo de 2018 y finaliz&#243; en noviembre de 2019&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Poblaci&#243;n</span><p id="par0020" class="elsevierStylePara elsevierViewall">Los pacientes elegibles eran adultos &#40;&#8805; 18 a&#241;os&#41; diagnosticados con psoriasis cr&#243;nica en placas que hab&#237;an iniciado tratamiento con apremilast 6 &#177; 1 meses antes de la inclusi&#243;n en el estudio&#46; Se invit&#243; a participar a todos los pacientes que cumpl&#237;an dichos criterios de forma consecutiva&#44; independientemente de que hubieran suspendido apremilast en el momento de su evaluaci&#243;n&#46; La inclusi&#243;n en el estudio no interfiri&#243; en ning&#250;n caso con la pr&#225;ctica habitual de cada dermat&#243;logo&#46; El &#250;nico criterio de exclusi&#243;n fue la participaci&#243;n de los pacientes en alg&#250;n ensayo cl&#237;nico&#46; El estudio se realiz&#243; de acuerdo con la Declaraci&#243;n de Helsinki y fue aprobado por los comit&#233;s &#233;ticos de los centros participantes&#46; Todos los participantes firmaron el consentimiento informado antes de la recopilaci&#243;n de datos&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Recopilaci&#243;n de datos</span><p id="par0025" class="elsevierStylePara elsevierViewall">El estudio se basa en una &#250;nica visita presencial a los 6 &#177; 1 meses del inicio de apremilast&#44; en la que se recogieron los datos de las historias cl&#237;nicas y de los cuestionarios completados por dermat&#243;logos y pacientes&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">De las historias cl&#237;nicas se recogieron los datos demogr&#225;ficos&#44; historial m&#233;dico&#44; comorbilidades&#44; gravedad de la enfermedad &#40;<span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#91;PASI&#93; y <span class="elsevierStyleItalic">Body Surface Area</span> &#91;BSA&#93;&#41;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a>&#44; manifestaciones cl&#237;nicas &#40;prurito&#44; fatiga&#44; u&#241;as&#44; cuero cabelludo&#44; palmoplantar&#44; psoriasis inversa genital y no genital&#44; pustulosis palmoplantar y artritis psori&#225;sica&#41;&#44; estado del tratamiento con apremilast &#40;fecha y motivos de discontinuaci&#243;n si aplica&#41;&#44; tratamientos previos para la psoriasis&#44; calidad de vida &#40;CdV&#44; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#91;DLQI&#93;&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> y acontecimientos adversos &#40;AAs&#41;&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Los dermat&#243;logos cumplimentaron tres cuestionarios de satisfacci&#243;n espec&#237;ficos del estudio que recog&#237;an informaci&#243;n sobre los motivos del uso de apremilast &#40;1&#41;&#44; los efectos del tratamiento sobre los s&#237;ntomas&#44; la tolerabilidad del tratamiento&#44; la efectividad de apremilast sobre las manifestaciones espec&#237;ficas de la psoriasis &#40;2&#41;&#44; el cumplimiento de las expectativas y el &#233;xito general &#40;3&#41;&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Los pacientes completaron tres cuestionarios&#58; <span class="elsevierStyleItalic">Patient Benefit Index</span> &#40;PBI&#41;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a>&#44; <span class="elsevierStyleItalic">Treatment Satisfaction Questionnaire for Medication</span> &#40;TSQM-9&#41;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a> y el cuestionario espec&#237;fico del estudio&#46; Dicho cuestionario recopil&#243; datos demogr&#225;ficos&#44; socioecon&#243;micos&#44; factores de estilo de vida y expectativas y experiencia con apremilast&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a> resume las principales herramientas de evaluaci&#243;n&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">An&#225;lisis estad&#237;stico</span><p id="par0050" class="elsevierStylePara elsevierViewall">Se analizaron los datos demogr&#225;ficos de los pacientes&#44; las caracter&#237;sticas de la enfermedad&#44; los resultados del tratamiento y los AAs mediante estad&#237;stica descriptiva&#46; Se calcularon los intervalos de confianza &#40;IC&#41; del 95&#37;&#46; Los valores ausentes no fueron imputados&#46; Los resultados se estratificaron seg&#250;n el estado de la terapia con apremilast&#58; en curso vs&#46; discontinuado&#46; Se calcularon las correlaciones entre las medidas de resultado&#46; Los an&#225;lisis estad&#237;sticos fueron realizados mediante el programa SAS versi&#243;n 9&#46;4&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Resultados</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Caracter&#237;sticas de la poblaci&#243;n</span><p id="par0055" class="elsevierStylePara elsevierViewall">En Espa&#241;a se invit&#243; a 86 pacientes a participar en el estudio APPRECIATE&#44; de los cuales 82 fueron incluidos en el estudio&#46; Finalmente&#44; 80 pacientes formaron parte de la poblaci&#243;n de seguridad y del conjunto de an&#225;lisis completo &#40;FAS&#41;&#59; dos pacientes &#40;2&#44;4&#37;&#41; fueron excluidos por no haber sido diagnosticados de psoriasis&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">En el momento de iniciar apremilast&#44; los pacientes presentaban una puntuaci&#243;n media basal para PASI y BSA &#40;desviaci&#243;n est&#225;ndar&#44; DE&#41; de 8&#44;3 &#40;5&#44;3&#41; y 11&#44;0 &#40;10&#44;8&#41;&#44; respectivamente&#46; Asimismo&#44; al inicio de apremilast&#44; la mayor&#237;a de los pacientes &#40;78&#44;6&#37;&#41; present&#243; una puntuaci&#243;n PASI &#60; 10 &#40;intensidad leve-moderada&#41; y la puntuaci&#243;n DLQI media &#40;DE&#41; fue 8&#44;9 &#40;6&#44;6&#41;&#44; mostrando un efecto moderado sobre la CdV &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; La principal sintomatolog&#237;a fue el prurito &#40;57&#44;5&#37;&#41; y la localizaci&#243;n m&#225;s frecuente fue el cuero cabelludo&#44; seguido de las u&#241;as &#40;42&#44;5&#37; y 33&#44;8&#37;&#44; respectivamente&#41;&#46; El 75&#44;0&#37; &#40;n &#61; 60&#41; de los pacientes presentaban comorbilidades asociadas &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; Al inicio del tratamiento con apremilast&#44; el 16&#44;3&#37; &#40;n &#61; 13&#41; y el 11&#44;3&#37; &#40;n &#61; 9&#41; de los pacientes recib&#237;an medicaci&#243;n para la ansiedad y la depresi&#243;n&#44; respectivamente&#46; La mayor&#237;a de los pacientes &#40;n &#61; 70&#59; 87&#44;5&#37;&#41; hab&#237;a recibido al menos un tratamiento sist&#233;mico previo para la psoriasis &#40;26 &#91;32&#44;5&#37;&#93; pacientes una terapia&#44; 25 &#91;31&#44;3&#37;&#93; pacientes dos terapias y 19 &#91;23&#44;8&#37;&#93; pacientes m&#225;s de dos terapias previas&#41; y seis &#40;7&#44;5&#37;&#41; manten&#237;an alg&#250;n otro tratamiento sist&#233;mico concomitante &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; La <a class="elsevierStyleCrossRef" href="#fig0010">figura 2</a> muestra las principales razones para considerar el tratamiento con apremilast&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Efectividad de apremilast</span><p id="par0065" class="elsevierStylePara elsevierViewall">El 58&#44;8&#37; &#40;n &#61; 47&#41; de los pacientes evaluados continuaban en tratamiento con apremilast despu&#233;s de seis meses&#46; Los pacientes que suspendieron el f&#225;rmaco lo utilizaron durante una media &#40;DE&#41; de 103&#44;5 &#40;64&#44;3&#41; d&#237;as&#46; Los principales motivos de discontinuaci&#243;n fueron la falta de eficacia &#40;n &#61; 13&#47;80&#59; 16&#44;3&#37;&#41; y motivos de seguridad&#47;tolerabilidad &#40;n &#61; 16&#47;80&#59; 20&#44;0&#37;&#41;&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">En los pacientes que continuaban con apremilast a los seis meses en los que se dispon&#237;a de las diferentes puntuaciones al inicio y al seguimiento&#44; la media de la puntuaci&#243;n PASI al seguimiento &#40;n &#61; 30&#47;47&#59; 63&#44;8&#37;&#41; fue de 3&#44;4 &#40;IC 95&#37;&#58; 2&#44;1-4&#44;7&#41;&#44; lo que supone una mejor&#237;a del 54&#44;8&#37; &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; El objetivo PASI75 fue alcanzado por el 36&#44;7&#37; &#40;n &#61; 11&#47;30&#41; de los pacientes&#44; y el 80&#44;0&#37; &#40;n &#61; 24&#47;30&#41; alcanz&#243; PASI&#60; 5 &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; De los pacientes que al inicio del tratamiento presentaban PASI&#60; 10 &#40;n &#61; 23&#41; el 26&#44;1&#37; &#40;n &#61; 6&#47;23&#59; IC 95&#37;&#58; 10&#44;2-48&#44;4&#37;&#41; alcanz&#243; PASI75 y el 78&#44;3&#37; &#40;n &#61; 18&#47;23&#41; PASI&#60; 5&#59; entre los pacientes con PASI&#8805; 10 al inicio &#40;n &#61; 7&#41;&#44; se alcanz&#243; PASI75 en cinco pacientes y PASI&#60; 5 en seis pacientes&#46; La media &#40;IC 95&#37;&#41; de la puntuaci&#243;n DLQI al seguimiento &#40;n &#61; 12&#47;47&#59; 25&#44;5&#37;&#41; fue de 2&#44;2 &#40;0&#44;7-3&#44;6&#41;&#44; lo que supone una mejor&#237;a media de 6&#44;2 puntos &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; Los siete pacientes con DLQI &#8805; 4 al inicio del tratamiento alcanzaron una mejor&#237;a &#8805; 4 puntos a los seis meses&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Satisfacci&#243;n del dermat&#243;logo con apremilast</span><p id="par0075" class="elsevierStylePara elsevierViewall">Seg&#250;n la evaluaci&#243;n por los dermat&#243;logos&#44; el 73&#44;8&#37; &#40;n &#61; 59&#41; de los pacientes presentaron mejor&#237;a en las valoraciones de aclaramiento general de la psoriasis&#44; el 61&#44;3&#37; &#40;n &#61; 49&#41; bienestar general y el 56&#44;3&#37; &#40;n &#61; 45&#41; en el objetivo de alcanzar una vida diaria normal&#46; Entre los pacientes que al inicio mostraban s&#237;ntomas y manifestaciones espec&#237;ficas de la psoriasis&#44; los dermat&#243;logos confirmaron una mejor&#237;a del prurito en el 80&#44;4&#37; &#40;37&#47;46&#41;&#44; 67&#44;6&#37; &#40;23&#47;34&#41; de las manifestaciones en cuero cabelludo&#44; 63&#44;0&#37; &#40;17&#47;27&#41; en la afectaci&#243;n ungueal y 55&#44;0&#37; &#40;11&#47;20&#41; en las lesiones palmoplantares&#46; Los dermat&#243;logos indicaron que los resultados obtenidos fueron superiores a sus expectativas en la mitad de los pacientes tratados &#40;50&#44;0&#37;&#59; n &#61; 40&#41;&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Satisfacci&#243;n del paciente con apremilast</span><p id="par0080" class="elsevierStylePara elsevierViewall">La puntuaci&#243;n PBI media &#40;DE&#41; para la poblaci&#243;n total fue 2&#44;2 &#40;1&#44;2&#41; y el 83&#44;2&#37; &#40;n &#61; 64&#41; de los pacientes alcanz&#243; PBI &#8805; 1 &#40;beneficio cl&#237;nicamente significativo&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>&#41;&#46; En los pacientes que se manten&#237;an con apremilast&#44; la media &#40;DE&#41; de la puntuaci&#243;n PBI fue 2&#44;8 &#40;0&#44;8&#41; y el 100&#44;0&#37; &#40;n &#61; 45&#41; alcanz&#243; PBI &#8805; 1 &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0085" class="elsevierStylePara elsevierViewall">En los pacientes que continuaban con apremilast&#44; la puntuaci&#243;n media global &#40;DE&#41; de satisfacci&#243;n con el tratamiento &#40;cuestionario TSQM-9&#41; fue 66&#44;6 &#40;22&#44;9&#41;&#44; 76&#44;6 &#40;21&#44;0&#41; y 70&#44;5 &#40;21&#44;5&#41; para las subescalas de efectividad&#44; conveniencia y satisfacci&#243;n global&#44; respectivamente &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>&#41;&#46; En este mismo grupo de pacientes&#44; se observ&#243; una reducci&#243;n de los s&#237;ntomas de psoriasis durante el primer mes de tratamiento en el 48&#44;9&#37; &#40;n &#61; 23&#41;&#44; y el 59&#44;6&#37; &#40;n &#61; 28&#41; consider&#243; que apremilast le permit&#237;a llevar una vida cotidiana normal&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Correlaci&#243;n de las evaluaciones cl&#237;nicas&#44; expectativas y beneficios reportados por dermat&#243;logos y pacientes</span><p id="par0090" class="elsevierStylePara elsevierViewall">La correlaci&#243;n entre el cambio porcentual respecto al valor basal del PASI y el beneficio del tratamiento &#40;puntuaci&#243;n del PBI global&#41; reportado por los pacientes mostr&#243; una correlaci&#243;n negativa muy baja &#40;coeficiente de correlaci&#243;n &#61; -0&#44;14299&#41;&#44; lo que significa que no hab&#237;a mucha correlaci&#243;n&#44; es decir&#44; que la respuesta cut&#225;nea no fue suficiente para explicar el beneficio del paciente con el tratamiento &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>&#41;&#46; Por el contrario&#44; la evaluaci&#243;n de los dermat&#243;logos sobre el &#233;xito general de apremilast y la percepci&#243;n de los pacientes sobre el beneficio del tratamiento &#40;puntuaci&#243;n del PBI global&#41; mostr&#243; una correlaci&#243;n positiva alta &#40;coeficiente de correlaci&#243;n&#61; 0&#44;63629&#41;&#46; Los casos en los que los dermat&#243;logos indicaron que sus expectativas se alcanzaron o superaron coincidieron con la percepci&#243;n de los pacientes de un alto beneficio &#40;PBI &#8805; 3&#41;&#44; y viceversa&#46;</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">En la <a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a> se muestran los niveles de satisfacci&#243;n de dermat&#243;logos y pacientes respecto al efecto del tratamiento con apremilast sobre los s&#237;ntomas&#46; Concretamente&#44; la satisfacci&#243;n de los pacientes que continuaban en tratamiento con apremilast fue del 63&#44;8&#37; en la respuesta r&#225;pida&#44; 66&#44;0&#37; en la respuesta mantenida&#44; 70&#44;2&#37; en la reducci&#243;n del prurito&#44; 70&#44;2&#37; en la mejor&#237;a del estado de &#225;nimo y 72&#44;3&#37; en la sensaci&#243;n de bienestar general&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Seguridad</span><p id="par0100" class="elsevierStylePara elsevierViewall">Se registraron un total de 80 AAs en 45 pacientes &#40;56&#44;3&#37;&#41;&#46; En la gran mayor&#237;a de estos casos &#40;n &#61; 44 &#91;55&#44;0&#37;&#93;&#41;&#44; dichos AAs se relacionaron con el tratamiento&#44; y en 18 pacientes &#40;22&#44;5&#37;&#41; condujeron a la retirada de apremilast&#46; Los AAs reportados con mayor frecuencia fueron diarrea &#40;27&#44;5&#37;&#41; y n&#225;useas &#40;18&#44;8&#37;&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;&#46; Tres pacientes sufrieron insomnio &#40;uno de estos casos&#44; en tratamiento previo por ansiedad&#41;&#46; No se registraron AA graves&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Discusi&#243;n</span><p id="par0105" class="elsevierStylePara elsevierViewall">El estudio observacional APPRECIATE demuestra que los pacientes tratados con apremilast en condiciones de pr&#225;ctica habitual en Espa&#241;a&#44; presentaban caracter&#237;sticas diferentes a las observadas en los ensayos cl&#237;nicos<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5</span></a>&#58; afectaci&#243;n cut&#225;nea m&#225;s moderada &#40;puntuaci&#243;n PASI media &#61; 8&#44;3 con puntuaciones &#60; 10 en el 78&#44;6&#37; de los pacientes&#41; junto a impacto sustancial en la CdV &#40;puntuaci&#243;n DLQI media &#61; 8&#44;9&#41;&#46; Publicaciones previas &#40;incluida la de la poblaci&#243;n europea del estudio APPRECIATE&#41; ya hab&#237;an confirmado esta tendencia a tratar pacientes menos graves&#44; a pesar de que asocian un elevado impacto en la CdV<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5&#44;6&#44;11&#8211;16</span></a>&#46; Esta observaci&#243;n sugiere que apremilast puede satisfacer una necesidad de tratamiento en pacientes con una afecci&#243;n cut&#225;nea m&#225;s moderada&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Aunque los &#237;ndices PASI y DLQI son herramientas usadas com&#250;nmente para evaluar la gravedad de la enfermedad y la eficacia del tratamiento&#44; en el presente estudio su uso s&#243;lo pudo ser recogido&#44; al inicio del tratamiento y al seguimiento&#44; en el 37&#44;5 y 15&#44;0&#37; de los pacientes&#44; respectivamente&#46; Estos datos sugieren que estas escalas no se usan de manera consistente en la pr&#225;ctica diaria&#44; por lo que parece necesario mejorar la evaluaci&#243;n de las necesidades de los pacientes y la efectividad del tratamiento m&#225;s all&#225; de las medidas tradicionales&#46; En este sentido&#44; el presente an&#225;lisis muestra una baja correlaci&#243;n negativa entre el porcentaje de cambio en PASI a los seis meses de tratamiento y el beneficio global del tratamiento reportado por los pacientes &#40;PBI&#41;&#44; lo que sugiere que la mejor&#237;a de las lesiones visibles no fue suficiente para explicar el beneficio del paciente&#46; Adem&#225;s&#44; los pacientes tambi&#233;n reportaron su satisfacci&#243;n con la respuesta r&#225;pida y mantenida a apremilast&#44; as&#237; como con la reducci&#243;n del prurito&#44; la mejor&#237;a del estado de &#225;nimo y la sensaci&#243;n de bienestar general&#46; Dermat&#243;logos y pacientes reportaron una satisfacci&#243;n similar con apremilast&#46; Adem&#225;s&#44; la evaluaci&#243;n de los dermat&#243;logos sobre el &#233;xito general de apremilast en el logro de las expectativas y la percepci&#243;n de los pacientes sobre el beneficio obtenido mostraron una correlaci&#243;n positiva alta&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Por otra parte&#44; el grupo de pacientes que mantuvieron tratamiento con apremilast durante seis meses mostraron mejor&#237;a en PASI &#40;reducci&#243;n de 5&#44;5 puntos&#41;&#44; BSA &#40;reducci&#243;n del 10&#44;6&#37; de la superficie corporal&#41;&#44; DLQI &#40;reducci&#243;n de 6&#44;2 puntos&#41;&#44; PBI &#40;todos los pacientes alcanzaron PBI &#8805; 1&#44; valor considerado como beneficio cl&#237;nicamente significativo&#41;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a> y TSQM-9 &#40;satisfacci&#243;n global &#61; 70&#44;5 puntos&#41;&#46; Los valores alcanzados para PASI &#40;3&#44;4&#41;&#44; BSA &#40;2&#44;6&#41; y DLQI &#40;2&#44;2&#41; fueron consistentes con los observados en el estudio del Grupo Espa&#241;ol de Psoriasis &#40;GPs&#41; &#40;3&#44;6&#59; 3&#44;1 &#91;semana 12&#93;&#47;2&#44;5 &#91;semana 52&#93;&#59; 5&#44;2 &#91;semana 12&#93;&#47;2&#44;3 &#91;semana 52&#93;&#44; respectivamente&#41;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">16</span></a> y en el an&#225;lisis intermedio del estudio APPROPRIATE &#40;2&#44;6&#59; 3&#44;7 y 53&#37; valores de 0-1&#44; respectivamente&#41;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">17</span></a>&#46; En el estudio APPRECIATE multinacional&#44; los valores alcanzados &#40;PASI &#61; 4&#44;6&#59; BSA &#61; 10&#44;9&#59; DLQI &#61; 5&#44;7&#41; fueron ligeramente m&#225;s elevados&#44; pero se debe considerar que los valores de partida eran tambi&#233;n mayores &#40;PASI &#61; 12&#44;5&#59; BSA &#61; 25&#44;4&#59; DLQI &#61; 13&#44;4&#41;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a>&#46; La persistencia a los seis meses fue del 58&#44;8&#37; en este estudio frente al 72&#44;3&#37; observado en el estudio APPRECIATE multinacional&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">El perfil de seguridad de apremilast confirm&#243; el ya observado en los ensayos cl&#237;nicos<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5</span></a>&#46; Al igual que en otros estudios de pr&#225;ctica cl&#237;nica&#44; la proporci&#243;n de AAs fue menor que la de los ensayos &#40;47-59 vs&#46; 67-79&#37;&#44; respectivamente&#41; pero&#44; por el contrario la proporci&#243;n de pacientes que discontinuaron apremilast debido a AAs fue mayor &#40;16-23 vs&#46; 6&#44;6-7&#44;3&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5&#44;16&#44;18&#44;19</span></a>&#46; Pese a que la ficha t&#233;cnica de apremilast advierte sobre su uso cauteloso en pacientes con depresi&#243;n<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#44; el 11&#44;3&#37; de los pacientes tratados en este estudio estaban recibiendo tratamiento antidepresivo cuando iniciaron apremilast&#59; ninguno de estos pacientes present&#243; AA relacionados con trastornos psiqui&#225;tricos&#46; Por otra parte&#44; en este estudio no se han reportado infecciones en v&#237;as respiratorias superiores&#44; AA reportado con una frecuencia del 8&#44;4&#37; y principalmente de intensidad leve en la ficha t&#233;cnica<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">En este estudio se incluyeron todos los pacientes consecutivos que pudieron ser contactados seis meses &#40;&#177; 1 mes&#41; despu&#233;s del inicio del tratamiento &#40;pudiendo pacientes haber completado o no los seis meses de tratamiento con apremilast&#41; con la finalidad de minimizar el sesgo en la selecci&#243;n de los pacientes&#46; No obstante&#44; este estudio presenta algunas limitaciones inherentes a su dise&#241;o retrospectivo&#44; su corto periodo de seguimiento y las condiciones de pr&#225;ctica cl&#237;nica&#44; as&#237; como la inexistencia de un grupo control o la disponibilidad de datos en algunos pacientes&#46; El hecho que haya un porcentaje bajo de pacientes con valores PASI y DLQI disponibles puede haber influenciado en los an&#225;lisis realizados&#46; Se reconoce un potencial sesgo positivo de selecci&#243;n porque los pacientes con experiencia positiva con apremilast pudieron ser m&#225;s propensos a aceptar participar en el estudio&#46; Finalmente&#44; como los cuestionarios fueron rellenados retrospectivamente&#44; no podemos descartar el sesgo de memoria&#44; aunque la duraci&#243;n del estudio &#40;seis meses&#41; fue especialmente escogida para minimizar este riesgo&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Conclusiones</span><p id="par0130" class="elsevierStylePara elsevierViewall">El estudio APPRECIATE muestra que los pacientes que iniciaron apremilast en la pr&#225;ctica cl&#237;nica en Espa&#241;a presentaban una afectaci&#243;n cut&#225;nea menor que aquellos reclutados en ensayos cl&#237;nicos&#46; Aun as&#237;&#44; se confirma un impacto inesperadamente elevado en la CdV de estos pacientes&#46; Esto sugiere que&#44; a la hora de evaluar la importancia real de la enfermedad&#44; deben considerarse y medirse otros factores&#44; adem&#225;s del grado de afectaci&#243;n de la piel&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Los resultados del estudio muestran que a los seis meses del inicio de apremilast&#44; se observaron mejor&#237;as en las evaluaciones globales de la gravedad de la enfermedad &#40;PASI75 36&#44;7&#37;&#41;&#44; en la CdV &#40;DLQI medio se redujo m&#225;s de 6 puntos&#41; y en la satisfacci&#243;n de los pacientes que continuaban en tratamiento con apremilast &#40;63&#44;8&#37; en la respuesta r&#225;pida&#44; 66&#44;0&#37; en la respuesta mantenida&#44; 70&#44;2&#37; en la reducci&#243;n del prurito&#44; 70&#44;2&#37; en la mejor&#237;a del estado de &#225;nimo y 72&#44;3&#37; en la sensaci&#243;n de bienestar general&#41;&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Finalmente&#44; los resultados de este estudio resaltan la necesidad de definir la gravedad de la psoriasis de una manera m&#225;s completa&#44; incorporando medidas centradas en el paciente a la medici&#243;n de las escalas tradicionales&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Financiaci&#243;n</span><p id="par0145" class="elsevierStylePara elsevierViewall">Este estudio ha sido financiado por Celgene&#46; Amgen adquiri&#243; los derechos de Otezla&#174; &#40;apremilast&#41; en todo el mundo el 21 de noviembre de 2019&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Los investigadores cualificados pueden solicitar datos de estudios cl&#237;nicos de Amgen&#46; Los detalles completos est&#225;n disponibles en <a href="http://www.amgen.com/datasharing">http&#58;&#47;&#47;www&#46;amgen&#46;com&#47;datasharing</a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Conflicto de intereses</span><p id="par0155" class="elsevierStylePara elsevierViewall">Pedro Herranz&#58; investigador&#47;asesor&#47;conferenciante de AbbVie&#44; Almirall&#44; Amgen&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sandoz&#44; Sanofi y UCB Pharma&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Lidia Trasobares&#58; investigadora y&#47;o conferenciante de AbbVie&#44; Almirall&#44; Amgen&#44; Celgene&#44; Janssen&#44; LEO Pharma&#44; Meda y Novartis&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Almudena Mateu&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Esperanza Mart&#237;nez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">Ricardo Ruiz Villaverde conferenciante y&#47;o asesor de AbbVie&#44; Amgen&#44; Celgene&#44; LEO Pharma&#44; Lilly&#44; MSD&#44; Novartis y UCB Pharma&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Ofelia Baniandr&#233;s&#58; asesora y&#47;o conferenciante de AbbVie&#44; Celgene&#44; LEO Pharma&#44; Lilly MSD&#44; Novartis&#44; Janssen y Pfizer&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">Javier Mataix D&#237;az&#58; no declara ning&#250;n conflicto de intereses&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Natalia Jim&#233;nez G&#243;mez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">Marta Serra&#58; conferenciante de AbbVie&#44; Almirall&#44; Celgene&#44; Janssen&#44; LEO Pharma y Lilly&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Diana Patricia Ruiz Genao asesora y&#47;o conferenciante honoraria de AbbVie&#44; Amgen&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Novartis y Pfizer&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">Noelia Rivera&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">Jes&#250;s Tercedor S&#225;nchez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">Carmen Garc&#237;a&#58; anterior empleada de Amgen&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Myriam Cordey&#58; empleados de Amgen &#40;Europe&#41; GmbH&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Enrique Herrera Acosta&#58; no declaran conflictos de inter&#233;s&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1581253"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1581251"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Antecedentes y objetivos"
            ]
            1 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "M&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1423454"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1581252"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Background and objectives"
            ]
            1 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0045"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1423455"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Dise&#241;o del estudio"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Poblaci&#243;n"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Recopilaci&#243;n de datos"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "An&#225;lisis estad&#237;stico"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Resultados"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Caracter&#237;sticas de la poblaci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Efectividad de apremilast"
            ]
            2 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Satisfacci&#243;n del dermat&#243;logo con apremilast"
            ]
            3 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Satisfacci&#243;n del paciente con apremilast"
            ]
            4 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Correlaci&#243;n de las evaluaciones cl&#237;nicas&#44; expectativas y beneficios reportados por dermat&#243;logos y pacientes"
            ]
            5 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Seguridad"
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Discusi&#243;n"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conclusiones"
        ]
        10 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Financiaci&#243;n"
        ]
        11 => array:2 [
          "identificador" => "sec0085"
          "titulo" => "Conflicto de intereses"
        ]
        12 => array:2 [
          "identificador" => "xack558531"
          "titulo" => "Agradecimientos"
        ]
        13 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2021-02-18"
    "fechaAceptado" => "2021-05-09"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1423454"
          "palabras" => array:4 [
            0 => "Apremilast"
            1 => "Psoriasis"
            2 => "Pr&#225;ctica cl&#237;nica"
            3 => "Beneficios terap&#233;uticos"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1423455"
          "palabras" => array:4 [
            0 => "Apremilast"
            1 => "Psoriasis"
            2 => "Clinical practice"
            3 => "Therapeutic benefits"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Antecedentes y objetivos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Es conveniente ampliar el conocimiento del manejo de apremilast en pr&#225;ctica cl&#237;nica&#46; El estudio APPRECIATE &#40;NCT02740218&#41; pretende describir las caracter&#237;sticas de pacientes con psoriasis tratados con apremilast&#44; evaluar sus perspectivas y las de sus dermat&#243;logos&#44; y los resultados obtenidos en la pr&#225;ctica cl&#237;nica espa&#241;ola&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">M&#233;todos</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Estudio observacional&#44; retrospectivo&#44; transversal y multic&#233;ntrico en pacientes con psoriasis cr&#243;nica en placas&#44; a los que se visit&#243; seis &#40;&#177; 1&#41; meses despu&#233;s de iniciar apremilast&#46; Los datos se obtuvieron de las historias cl&#237;nicas y cuestionarios realizados por pacientes y dermat&#243;logos&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Resultados</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Se evaluaron 80 pacientes&#44; al iniciar apremilast presentaban <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; medio &#40;desviaci&#243;n est&#225;ndar&#44; DE&#41; &#61; 8&#44;3 &#40;5&#44;3&#41; y <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; medio &#40;DE&#41; &#61; 8&#44;9 &#40;6&#44;6&#41;&#46; A los seis meses&#44; el 58&#44;8&#37; &#40;n &#61; 47&#41; continuaba con apremilast &#40;discontinuaciones&#58; falta de eficacia &#91;16&#44;3&#37;&#93;&#44; seguridad&#47;tolerabilidad &#91;20&#44;0&#37;&#93;&#41;&#46; En pacientes que continuaban en tratamiento&#44; el PASI75 fue alcanzado por el 36&#44;7&#37;&#59; la puntuaci&#243;n DLQI media &#40;IC 95&#37;&#41; fue 2&#44;2 &#40;0&#44;7-3&#44;6&#41; y <span class="elsevierStyleItalic">Patient Benefit Index</span> medio &#40;DE&#41; 2&#44;8 &#40;0&#44;8&#41;&#46; El cumplimiento de las expectativas de los dermat&#243;logos se correlacion&#243; con los beneficios descritos por los pacientes &#40;r &#61; 0&#44;636&#41;&#46; El 56&#44;3&#37; report&#243; acontecimientos adversos &#40;diarrea y n&#225;useas los m&#225;s frecuentes&#41;&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusiones</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Los pacientes que recibieron apremilast durante seis meses en la pr&#225;ctica cl&#237;nica en Espa&#241;a reportaron una mejor&#237;a en su calidad de vida &#40;DLQI medio se redujo m&#225;s de seis puntos&#41; y en la gravedad de la enfermedad &#40;PASI75 alcanzado por m&#225;s de un tercio de los pacientes&#41;&#44; a pesar de presentar una afectaci&#243;n cut&#225;nea menor que aquellos pacientes incluidos en ensayos cl&#237;nicos&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Antecedentes y objetivos"
          ]
          1 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "M&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Background and objectives</span><p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">It is necessary to expand the knowledge in the use of apremilast in clinical practice&#46; The APPRECIATE study &#40;NCT02740218&#41; aims to describe the characteristics of patients with psoriasis treated with apremilast&#44; to evaluate their perspectives and those of dermatologists&#44; as well as the outcomes obtained in clinical practice in Spain&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Methods</span><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Observational&#44; retrospective&#44; cross-sectional&#44; multicenter study of patients with chronic plaque psoriasis who could be contacted 6 &#40;&#177;1&#41; months after apremilast initiation&#46; The data were obtained from medical records and questionnaires from patients and physicians&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Results</span><p id="spar0125" class="elsevierStyleSimplePara elsevierViewall">A total of 80 patients were evaluated&#59; at apremilast onset&#44; they showed mean &#40;standard deviation&#44; SD&#41; Psoriasis Area and Severity Index &#40;PASI&#41; &#61; 8&#46;3 &#40;5&#46;3&#41;&#44; mean &#40;SD&#41; Dermatology Life Quality Index &#40;DLQI&#41; &#61; 8&#46;9 &#40;6&#46;6&#41;&#46; At six months&#44; 58&#46;8&#37; &#40;n&#61;47&#41; of patients continued apremilast treatment &#40;discontinuations due to lack of efficacy &#91;16&#46;3&#37;&#93;&#44; safety&#47;tolerability &#91;20&#46;0&#37;&#93;&#41;&#46; In patients continuing treatment&#44; PASI75 was achieved by 36&#46;7&#37; of patients&#59; mean &#40;95&#37; CI&#41; DLQI score was 2&#46;2 &#40;0&#46;7-3&#46;6&#41; and mean &#40;SD&#41; Patient Benefit Index score was 2&#46;8 &#40;0&#46;8&#41;&#46; Compliance with physicians&#8217; expectations was correlated with benefits reported by patients &#40;r&#61;0&#46;636&#41;&#46; Adverse events were reported by 56&#46;3&#37; of patients &#40;the most common were diarrhoea and nausea&#41;&#46;</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Conclusions</span><p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">Patients receiving apremilast for 6 months in Spanish clinical practice&#44; reported substantial improvements in their quality of life &#40;mean DLQI reduced by more than 6 points&#41; and disease severity &#40;PASI75 achieved by over one-third of patients&#41;&#44; despite less skin involvement than patients who enrolled in clinical trials&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Background and objectives"
          ]
          1 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0045"
            "titulo" => "Conclusions"
          ]
        ]
      ]
    ]
    "multimedia" => array:11 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2735
            "Ancho" => 2925
            "Tamanyo" => 417255
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Dise&#241;o del estudio&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1429
            "Ancho" => 2508
            "Tamanyo" => 156315
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Principales razones para considerar el tratamiento con apremilast&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2154
            "Ancho" => 2925
            "Tamanyo" => 238175
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Porcentaje de pacientes por categor&#237;as de la puntuaci&#243;n global PBI &#40;<span class="elsevierStyleItalic">Patient Benefit Index</span>&#41; a los seis &#40;&#177;1&#41; meses de iniciar tratamiento con apremilast&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figura 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 2334
            "Ancho" => 2925
            "Tamanyo" => 261868
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Calificaciones de satisfacci&#243;n de los pacientes mediante el <span class="elsevierStyleItalic">Treatment Satisfaction Questionnaire for Medication</span> &#40;TSQM-9&#41;&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 1940
            "Ancho" => 2925
            "Tamanyo" => 181706
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Correlaci&#243;n entre el cambio porcentual respecto al valor inicial en el <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; y el beneficio global reportado por el paciente mediante el <span class="elsevierStyleItalic">Patient Benefit Index</span> &#40;PBI&#41;&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#205;ndice o cuestionario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Objetivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Puntuaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Body Surface Area &#40;BSA&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medir la superficie corporal afectada por las lesiones de psoriasis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leve&#58; &#60; 3&#37; de la superficie&#59; Moderada&#58; 3-10&#37;&#59; Grave&#58; &#62; 10&#37;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis Area and Severity Index &#40;PASI&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar severidad de cada lesi&#243;n &#40;en base a eritema&#44; infiltraci&#243;n y descamaci&#243;n&#41; y el &#225;rea que afecta &#40;cabeza&#44; tronco&#44; extremidades superiores e inferiores&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leve&#58; 0-5&#59; Moderada&#58; 5-10&#59; Grave&#58; &#62; 10&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Physician&#39;s Global Assessment &#40;PGA&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar la intensidad de las lesiones&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Blanqueada&#58; 0&#59; Casi blanqueada&#58; 1&#59; Leve&#58; 2&#59; Leve a moderada&#58; 3&#59; Moderada&#58; 4&#59; Moderada a grave&#58; 5&#59; Grave&#58; 6&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatology Life Quality Index &#40;DLQI&#41;<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar el efecto de la enfermedad en la calidad de vida&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sin efecto&#58; 0-1&#59; Efecto m&#237;nimo&#58; 2-5&#59; Efecto moderado&#58; 6-10&#59; Muy grande&#58; 11-20&#59; Extremadamente grande&#58; 21-30&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Patient Benefit Index &#40;PBI&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Valorar el beneficio que aporta el tratamiento desde la perspectiva del paciente en base a un cuestionario sobre las necesidades terap&#233;uticas del paciente y otro sobre el beneficio alcanzado por el tratamiento&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Sin beneficio&#58; 0&#59; Beneficio m&#237;nimo&#58; 1&#59; Beneficio m&#225;ximo&#58; 4&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Treatment Satisfaction Questionnaire for Medication &#40;TSQM-9&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Valorar la satisfacci&#243;n con el tratamiento en t&#233;rminos de efectividad&#44; conveniencia y satisfacci&#243;n global&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">De 0-100&#44; donde 100 representa la m&#225;xima satisfacci&#243;n&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708763.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Fuente&#58; Chalmers<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a></p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Fuente&#58; Finlay et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Fuente&#58; Feuerhahn et al&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a></p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Fuente&#58; Atkinson et al&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a></p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Principales herramientas de evaluaci&#243;n utilizadas</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pacientes &#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Datos demogr&#225;ficos</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Edad &#40;a&#241;os&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#44;4 &#40;15&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hombres&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Peso &#40;kg&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&#44;4 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#44;8 &#40;5&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fumador actualmente&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;30&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Consumidor de alcohol&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;38&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Caracter&#237;sticas de la enfermedad</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tiempo desde el diagn&#243;stico &#40;a&#241;os&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#44;9 &#40;12&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#40;n &#61; 56&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;3 &#40;5&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#60; 10&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;78&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#8805; 10&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;21&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BSA &#40;n &#61; 42&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&#44;0 &#40;10&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PGA &#40;n &#61; 73&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;7 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>DLQI &#40;n &#61; 30&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;9 &#40;6&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pacientes con alguna comorbilidad&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60 &#40;75&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Comorbilidades &#40;&#62; 5&#37; de pacientes&#41;&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome metab&#243;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28 &#40;35&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipertensi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Depresi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Localizaci&#243;n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cuero cabelludo&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;42&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>U&#241;as&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;33&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Genital&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;13&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psoriasis palmoplantar&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;25&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pustulosis palmoplantar&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;6&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inversa no genital&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;6&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ntomatolog&#237;a de la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurito&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;57&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fatiga&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;13&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tratamientos previos para la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sist&#233;mico convencional<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">&#8225;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63 &#40;78&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fototerapia<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">&#8224;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;32&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Biol&#243;gico<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">&#167;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Razones para finalizar los tratamientos previos</span><a class="elsevierStyleCrossRef" href="#tblfn0040">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Falta de eficacia&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52 &#40;65&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Efectos adversos&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Coste&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Medicaci&#243;n concomitante para la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UVA&#47;UVB&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;3&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Glucocorticoides&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Metotrexato&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>nbUVB&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708761.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Tratamiento sist&#233;mico convencional incluy&#243; metotrexato &#40;n &#61; 38&#59; 47&#44;5&#37;&#41;&#44; acitretina &#40;n &#61; 25&#59; 31&#44;3&#37;&#41;&#44; retinoides &#40;n &#61; 16&#59; 20&#44;0&#37;&#41;&#44; ciclosporina &#40;n &#61; 14&#59; 17&#44;5&#37;&#41;&#44; alitretino&#237;na &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; &#225;cido fum&#225;rico &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; sulfasalazina &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Fototerapia incluy&#243; UVA&#47;UVB &#40;n &#61; 17&#59; 21&#44;3&#37;&#41;&#44; psoraleno &#43; UVA &#40;n &#61; 7&#59; 8&#44;8&#37;&#41;&#44; nbUVB &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Tratamiento biol&#243;gico incluy&#243; etanercept &#40;n &#61; 5&#59; 6&#44;3&#37;&#41;&#44; ustekinumab &#40;n &#61; 5&#59; 6&#44;3&#37;&#41;&#44; secukinumab &#40;n &#61; 4&#59; 5&#44;0&#37;&#41;&#44; adalimumab &#40;n &#61; 3&#59; 3&#44;8&#37;&#41;&#44; ixekizumab &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; efalizumab &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#44; infliximab &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">Se pod&#237;a indicar m&#225;s de una raz&#243;n para cada paciente&#46;</p> <p class="elsevierStyleNotepara" id="npar0045">BSA&#58; Body Surface Area&#59; DE&#58; desviaci&#243;n est&#225;ndar&#59; DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; IMC&#58; &#237;ndice de masa corporal&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">Physician&#39;s Global Assessment</span>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Datos demogr&#225;ficos y caracter&#237;sticas de la enfermedad al inicio de apremilast</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Evaluaci&#243;n cl&#237;nica<a class="elsevierStyleCrossRef" href="#tblfn0045">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Al inicio de apremilast&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">A los 6 meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cambio absoluto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI &#40;n &#61; 30&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;9 &#40;6&#44;4-11&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;4 &#40;2&#44;1-4&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-5&#44;5 &#40;-8&#44;3- -2&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI75 &#40;n &#61; 30&#41;&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;36&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI&#60; 5 &#40;n &#61; 30&#41;&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;16&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;80&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BSA &#40;n &#61; 20&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#44;3 &#40;7&#44;0-19&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;6 &#40;1&#44;6-3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10&#44;6 &#40;-16&#44;8- -4&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PGA &#40;n &#61; 44&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;8 &#40;2&#44;4-3&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#44;9 &#40;1&#44;6-2&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-0&#44;9 &#40;-1&#44;2- -0&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">DLQI &#40;n &#61; 12&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;3 &#40;3&#44;5-13&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;2 &#40;0&#44;7-3&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-6&#44;2 &#40;-10&#44;2- -2&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708765.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Datos de pacientes que a los seis meses continuaban en tratamiento con apremilast en los que se ten&#237;a el dato al inicio y al seguimiento&#46;</p> <p class="elsevierStyleNotepara" id="npar0055">BSA&#58; Body Surface Area&#59; DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; IC&#44; intervalo de confianza&#59; NA&#58; no aplica&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">Physician&#39;s Global Assessment</span>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Evoluci&#243;n de las evaluaciones cl&#237;nicas</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Beneficios<a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los dermat&#243;logos&#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los pacientes&#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los pacientes que contin&#250;an en tratamiento&#40;n &#61; 47&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta r&#225;pida&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30 &#40;63&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta mantenida&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49 &#40;61&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;45&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;66&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n notable de la psoriasis en placa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50 &#40;62&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32 &#40;40&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;53&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aclaramiento de &#225;reas espec&#237;ficas<a class="elsevierStyleCrossRef" href="#tblfn0055"><span class="elsevierStyleSup">&#167;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42 &#40;52&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40 &#40;50&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;66&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n del prurito&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;60&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45 &#40;56&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;70&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n del dolor articular&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;16&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;32&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;48&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n de la fatiga&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;25&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;42&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a del estado de &#225;nimo&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;70&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a del bienestar general&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;57&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;72&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708764.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0060">Se muestra recuento y porcentaje para la respuesta &#171;de acuerdo&#187; o &#171;totalmente de acuerdo&#187; a la pregunta para el dermat&#243;logo &#171;&#191;De qu&#233; manera cree que apremilast ha ayudado en el tratamiento de la psoriasis de este paciente&#63;&#187; y a la pregunta para el paciente &#171;&#191;De qu&#233; manera cree que apremilast ha ayudado en el tratamiento de su psoriasis&#63;&#187;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0055"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0065">Por ejemplo cuero cabelludo&#44; manos&#44; plantas de los pies&#44; u&#241;as y&#47;o genitales&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Niveles de satisfacci&#243;n de dermat&#243;logos y pacientes respecto al efecto del tratamiento sobre los s&#237;ntomas &#40;datos de los cuestionarios espec&#237;ficos&#41;</p>"
        ]
      ]
      9 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabla 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos &#40;AAs&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Poblaci&#243;n de seguridad &#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con alg&#250;n AA&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45 &#40;56&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con AA graves&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con AA que llevan a la retirada de la medicaci&#243;n&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;22&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">AA que suceden en &#8805;5&#37; de los pacientes&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N&#225;useas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>V&#243;mito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cefalea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">AA que llevan a la retirada de la medicaci&#243;n &#40;&#8805;5&#37; de los pacientes&#41;&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N&#225;useas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>V&#243;mito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;5&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cefalea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;5&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pacientes con p&#233;rdida de peso&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cambios en el peso&#44; media &#40;DE&#41;&#44; kg<a class="elsevierStyleCrossRef" href="#tblfn0065"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-5&#44;3 &#40;4&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cambios en el peso&#44; media &#40;DE&#41;&#44; kg<a class="elsevierStyleCrossRef" href="#tblfn0070"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;2 &#40;2&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708762.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0060"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0070">Se muestra el n&#250;mero de pacientes&#44; el porcentaje es en base al n&#250;mero total de pacientes&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0065"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0075">Para los pacientes que reportaron p&#233;rdida de peso&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0070"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0080">Para la totalidad de pacientes con datos disponibles del peso&#46;</p> <p class="elsevierStyleNotepara" id="npar0085">AA&#58; acontecimiento adverso&#59; DE&#58; desviaci&#243;n est&#225;ndar&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Seguridad con apremilast</p>"
        ]
      ]
      10 => array:5 [
        "identificador" => "fig0030"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1075
            "Ancho" => 1333
            "Tamanyo" => 171831
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:19 [
            0 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "otezla-epar-product-information&#95;en&#46;pdf&#46; &#40;Consultado 23 Jul 2020&#41;&#46; https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;documents&#47;product-information&#47;otezla-epar-product-information&#95;en&#46;pdf"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Apremilast&#44; an oral phosphodiesterase 4 &#40;PDE4&#41; inhibitor&#44; in patients with moderate to severe plaque psoriasis&#58; Results of a phase III&#44; randomized&#44; controlled trial &#40;Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis &#91;ESTEEM&#93; 1&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Papp"
                            1 => "K&#46; Reich"
                            2 => "C&#46;L&#46; Leonardi"
                            3 => "L&#46; Kircik"
                            4 => "S&#46; Chimenti"
                            5 => "R&#46;G&#46;B&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2015.03.049"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "73"
                        "paginaInicial" => "37"
                        "paginaFinal" => "49"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26089047"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of apremilast&#44; an oral phosphodiesterase 4 inhibitor&#44; in patients with moderate-to-severe plaque psoriasis over 52&#160;weeks&#58; a phase III&#44; randomized controlled trial &#40;ESTEEM 2&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Paul"
                            1 => "J&#46; Cather"
                            2 => "M&#46; Gooderham"
                            3 => "Y&#46; Poulin"
                            4 => "U&#46; Mrowietz"
                            5 => "C&#46; Ferrandiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14164"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "173"
                        "paginaInicial" => "1387"
                        "paginaFinal" => "1399"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26357944"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy and safety of apremilast&#44; etanercept and placebo in patients with moderate-to-severe plaque psoriasis&#58; 52-week results from a phase IIIb&#44; randomized&#44; placebo-controlled trial &#40;LIBERATE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "M&#46; Gooderham"
                            2 => "L&#46; Green"
                            3 => "A&#46; Bewley"
                            4 => "Z&#46; Zhang"
                            5 => "I&#46; Khanskaya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14015"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "31"
                        "paginaInicial" => "507"
                        "paginaFinal" => "517"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27768242"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis&#58; 52-Week Results of UNVEIL"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Stein Gold"
                            1 => "J&#46; Bagel"
                            2 => "M&#46; Lebwohl"
                            3 => "J&#46;M&#46; Jackson"
                            4 => "R&#46; Chen"
                            5 => "J&#46; Goncalves"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "17"
                        "paginaInicial" => "221"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29462231"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characteristics and Outcomes of Patients Treated With Apremilast in the Real World&#58; Results From the APPRECIATE Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "C&#46;E&#46; Kleyn"
                            2 => "C&#46; Conrad"
                            3 => "P&#46;G&#46; Sator"
                            4 => "M&#46; St&#229;hle"
                            5 => "K&#46; Eyerich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16431"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "123"
                        "paginaFinal" => "134"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32279378"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46;J&#46;G&#46; Chalmers"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2014.09.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin&#46;"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "57"
                        "paginaFinal" => "71"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25412783"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dermatology Life Quality Index &#40;DLQI&#41;&#8212;a simple practical measure for routine clinical use"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;Y&#46; Finlay"
                            1 => "G&#46;K&#46; Khan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2230.1994.tb01167.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "1994"
                        "volumen" => "19"
                        "paginaInicial" => "210"
                        "paginaFinal" => "216"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8033378"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46; Feuerhahn"
                            1 => "C&#46; Blome"
                            2 => "M&#46; Radtke"
                            3 => "M&#46; Augustin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00403-012-1256-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol Res&#46;"
                        "fecha" => "2012"
                        "volumen" => "304"
                        "paginaInicial" => "433"
                        "paginaFinal" => "441"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22722916"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hierarchical construct validity of the treatment satisfaction questionnaire for medication &#40;TSQM version II&#41; among outpatient pharmacy consumers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;J&#46; Atkinson"
                            1 => "R&#46; Kumar"
                            2 => "J&#46;C&#46; Cappelleri"
                            3 => "S&#46;L&#46; Hass"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1524-4733.2005.00066.x"
                      "Revista" => array:5 [
                        "tituloSerie" => "Value Health J Int Soc Pharmacoeconomics Outcomes Res&#46;"
                        "fecha" => "2005"
                        "volumen" => "8 &#40;Suppl 1&#41;"
                        "paginaInicial" => "S9"
                        "paginaFinal" => "S24"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Armstrong"
                            1 => "E&#46; Levi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "16"
                        "paginaInicial" => "1240"
                        "paginaFinal" => "1245"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Apremilast in psoriasis - a prospective real-world study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Vujic"
                            1 => "R&#46; Herman"
                            2 => "M&#46; Sanlorenzo"
                            3 => "C&#46; Posch"
                            4 => "B&#46; Monshi"
                            5 => "K&#46; Rappersberger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14598"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "254"
                        "paginaFinal" => "259"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28925560"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice&#58; A Canadian multicenter retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Ighani"
                            1 => "J&#46;R&#46; Georgakopoulos"
                            2 => "S&#46; Walsh"
                            3 => "N&#46;H&#46; Shear"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.060"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "623"
                        "paginaFinal" => "626"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28989112"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-World Experience With Apremilast in Treating Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;N&#46; Mayba"
                            1 => "M&#46;J&#46; Gooderham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1203475416676030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Cutan Med Surg&#46;"
                        "fecha" => "2017"
                        "volumen" => "21"
                        "paginaInicial" => "145"
                        "paginaFinal" => "151"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27846617"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Papadavid"
                            1 => "N&#46; Rompoti"
                            2 => "K&#46; Theodoropoulos"
                            3 => "G&#46; Kokkalis"
                            4 => "D&#46; Rigopoulos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14832"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "1173"
                        "paginaFinal" => "1179"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-world effectiveness and safety of apremilast in psoriasis at 52&#160;weeks&#58; a retrospective&#44; observational&#44; multicentre study by the Spanish Psoriasis Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Del Alc&#225;zar"
                            1 => "J&#46;A&#46; Su&#225;rez-P&#233;rez"
                            2 => "S&#46; Armesto"
                            3 => "R&#46; Rivera"
                            4 => "E&#46; Herrera-Acosta"
                            5 => "P&#46; Herranz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16439"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2020"
                        "volumen" => "34"
                        "paginaInicial" => "2821"
                        "paginaFinal" => "2829"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32271966"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig Sanz"
                            1 => "S&#46; Armesto"
                            2 => "E&#46; Montesinos"
                            3 => "A&#46;M&#46; Morales Callaghan"
                            4 => "R&#46; Rivera"
                            5 => "F&#46;J&#46; Latasa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "APPROPRIATE&#58; Estudio observacional prospectivo sobre los beneficios de apremilast en pacientes con psoriasis en placa tras otros tratamientos sist&#233;micos en condiciones de pr&#225;ctica cl&#237;nica en Espa&#241;a In&#58; Congreso virtual AEDV"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials&#58; A multicenter retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Ighani"
                            1 => "J&#46;R&#46; Georgakopoulos"
                            2 => "N&#46;H&#46; Shear"
                            3 => "S&#46; Walsh"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.067"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "801"
                        "paginaFinal" => "803"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29017843"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46;B&#46; Lee"
                            1 => "M&#46; Amin"
                            2 => "A&#46; Egeberg"
                            3 => "J&#46;J&#46; Wu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15061"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "e393"
                        "paginaFinal" => "e394"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29730885"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack558531"
        "titulo" => "Agradecimientos"
        "texto" => "<p id="par0230" class="elsevierStylePara elsevierViewall">Los autores quieren agradecer a todos los investigadores&#44; coordinadores y al personal de los centros participantes&#44; as&#237; como a los pacientes por su participaci&#243;n en este estudio&#46; El soporte en la redacci&#243;n m&#233;dica fue proporcionado por Irene Mansilla&#44; MSc&#44; de TFS S&#46;L&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021002027/v1_202110020514/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6163"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011200000009/v1_202110020514/S0001731021002027/v1_202110020514/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002027?idApp=UINPBA000044"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

ORIGINAL
Caracterización y resultados de pacientes tratados con apremilast en la práctica clínica habitual española: resultados del estudio APPRECIATE
Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
P. Herranza,
Corresponding author
pedro.herranz@salud.madrid.org

Autor para correspondencia.
, L. Trasobaresb, A. Mateuc, E. Martínezd, R. Ruiz-Villaverdee, O. Baniandrésf, J. Mataix Díazg, N. Jiménez-Gómezh, M. Serrai, D.P. Ruiz Genaoj, N. Riverak, J. Tercedor-Sánchezl, C. Garciam, M. Cordeyn, E. Herrera-Acostao
a Hospital Universitario La Paz, Madrid, España
b Hospital Universitario Príncipe de Asturias, Madrid, España
c Hospital Universitario Doctor Peset, Valencia, España
d Hospital Lluís Alcanyís Xàtiva, Valencia, España
e Hospital Clínico Universitario San Cecilio, Granada, España
f Hospital General Universitario Gregorio Marañón, Madrid, España
g Hospital Marina Baixa, Alicante, España
h Hospital Ramon y Cajal, Madrid, España
i Hospital Can Misses, Illes Balears, España
j Fundación Hospital Alcorcón, Madrid, España
k Hospital de Mollet, Barcelona, España
l Hospital Universitario Virgen de las Nieves, Granada, España
m Amgen Inc., Madrid, España
n Amgen Inc., Amgen (Europe) GmbH, Rotkreuz, Suiza
o Vithas Xanit Iinternational Hospital, Málaga, España
Ver más
Read
6193
Times
was read the article
2057
Total PDF
4136
Total HTML
Share statistics
 array:25 [
  "pii" => "S0001731021002027"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2021.05.010"
  "estado" => "S300"
  "fechaPublicacion" => "2021-10-01"
  "aid" => "2679"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2021;112:817-27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S1578219021002158"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2021.07.015"
      "estado" => "S300"
      "fechaPublicacion" => "2021-10-01"
      "aid" => "2679"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2021;112:817-27"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
        "titulo" => "Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain&#58; Results From the APPRECIATE Study"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "817"
            "paginaFinal" => "827"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Caracterizaci&#243;n y resultados de pacientes tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual espa&#241;ola&#58; resultados del estudio APPRECIATE"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0010"
            "etiqueta" => "Figure 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 1425
                "Ancho" => 2556
                "Tamanyo" => 179232
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0010"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Main reasons for considering apremilast treatment&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "P&#46; Herranz, L&#46; Trasobares, A&#46; Mateu, E&#46; Mart&#237;nez, R&#46; Ruiz-Villaverde, O&#46; Baniandr&#233;s, J&#46; Mataix D&#237;az, N&#46; Jim&#233;nez-G&#243;mez, M&#46; Serra, D&#46;P&#46; Ruiz Genao, N&#46; Rivera, J&#46; Tercedor-S&#225;nchez, C&#46; Garcia, M&#46; Cordey, E&#46; Herrera-Acosta"
            "autores" => array:15 [
              0 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz"
              ]
              1 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Trasobares"
              ]
              2 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Mateu"
              ]
              3 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Mart&#237;nez"
              ]
              4 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Ruiz-Villaverde"
              ]
              5 => array:2 [
                "nombre" => "O&#46;"
                "apellidos" => "Baniandr&#233;s"
              ]
              6 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Mataix D&#237;az"
              ]
              7 => array:2 [
                "nombre" => "N&#46;"
                "apellidos" => "Jim&#233;nez-G&#243;mez"
              ]
              8 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Serra"
              ]
              9 => array:2 [
                "nombre" => "D&#46;P&#46;"
                "apellidos" => "Ruiz Genao"
              ]
              10 => array:2 [
                "nombre" => "N&#46;"
                "apellidos" => "Rivera"
              ]
              11 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Tercedor-S&#225;nchez"
              ]
              12 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Garcia"
              ]
              13 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Cordey"
              ]
              14 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Herrera-Acosta"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731021002027"
          "doi" => "10.1016/j.ad.2021.05.010"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002027?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002158?idApp=UINPBA000044"
      "url" => "/15782190/0000011200000009/v1_202110091021/S1578219021002158/v1_202110091021/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S0001731021002039"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2021.05.011"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "2680"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "rev"
    "cita" => "Actas Dermosifiliogr. 2021;112:828-36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Novedades en Dermatolog&#237;a</span>"
      "titulo" => "Vacunas frente a SARS-CoV-2 y piel"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "828"
          "paginaFinal" => "836"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "SARS-CoV-2 Vaccines and the Skin"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0030"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 594
              "Ancho" => 1333
              "Tamanyo" => 113821
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Galv&#225;n-Casas, A&#46; Catal&#224;, C&#46; Mu&#241;oz-Santos"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Galv&#225;n-Casas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Catal&#224;"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Mu&#241;oz-Santos"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0030"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219021002407"
        "doi" => "10.1016/j.adengl.2021.07.028"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002407?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002039?idApp=UINPBA000044"
    "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021002039/v1_202110020514/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731021001988"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2021.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "2675"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2021;112:806-16"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
      "titulo" => "Descripci&#243;n basal de la cohorte nacional prospectiva de hemangiomas infantiles de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#46; Comparaci&#243;n de los pacientes tratados con propranolol en la pr&#225;ctica cl&#237;nica rutinaria y los datos del ensayo cl&#237;nico pivotal previo"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "806"
          "paginaFinal" => "816"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Baseline Description of the Spanish Academy of Dermatology Infantile Haemangioma Nationwide Prospective Cohort&#46; Comparison of Patients Treated with Propranolol in Routine Clinical Practice with Previous Pivotal Clinical Trial Data"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0005"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 1085
              "Ancho" => 1319
              "Tamanyo" => 102004
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C&#46; Cuenca-Barrales, E&#46; Baselga-Torres, J&#46; del Boz-Gonz&#225;lez, A&#46; Vicente, S&#46;I&#46; Palencia-P&#233;rez, M&#46; Campos-Dom&#237;nguez, M&#46; Valdivieso-Ramos, A&#46; Mart&#237;n-Santiago, M&#46;T&#46; Monserrat-Garc&#237;a, A&#46; Az&#243;n-Masoliver, M&#46; Feito-Rodr&#237;guez, J&#46;J&#46; Dom&#237;nguez-Cruz, E&#46; Ro&#233;-Crespo, C&#46; Salas-M&#225;rquez, A&#46; Giacaman, A&#46;I&#46; Lorente-Lavirgen, L&#46; Quintana-Castanedo, M&#46; de Vega-Mart&#237;nez, I&#46; Garc&#237;a-Doval, J&#46; Bernab&#233;u-Wittel"
          "autores" => array:20 [
            0 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Cuenca-Barrales"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Baselga-Torres"
            ]
            2 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "del Boz-Gonz&#225;lez"
            ]
            3 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Vicente"
            ]
            4 => array:2 [
              "nombre" => "S&#46;I&#46;"
              "apellidos" => "Palencia-P&#233;rez"
            ]
            5 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Campos-Dom&#237;nguez"
            ]
            6 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Valdivieso-Ramos"
            ]
            7 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Mart&#237;n-Santiago"
            ]
            8 => array:2 [
              "nombre" => "M&#46;T&#46;"
              "apellidos" => "Monserrat-Garc&#237;a"
            ]
            9 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Az&#243;n-Masoliver"
            ]
            10 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Feito-Rodr&#237;guez"
            ]
            11 => array:2 [
              "nombre" => "J&#46;J&#46;"
              "apellidos" => "Dom&#237;nguez-Cruz"
            ]
            12 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Ro&#233;-Crespo"
            ]
            13 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Salas-M&#225;rquez"
            ]
            14 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Giacaman"
            ]
            15 => array:2 [
              "nombre" => "A&#46;I&#46;"
              "apellidos" => "Lorente-Lavirgen"
            ]
            16 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Quintana-Castanedo"
            ]
            17 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "de Vega-Mart&#237;nez"
            ]
            18 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Garc&#237;a-Doval"
            ]
            19 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Bernab&#233;u-Wittel"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219021002419"
        "doi" => "10.1016/j.adengl.2021.08.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002419?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001988?idApp=UINPBA000044"
    "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021001988/v1_202110020514/es/main.assets"
  ]
  "es" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
    "titulo" => "Caracterizaci&#243;n y resultados de pacientes tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual espa&#241;ola&#58; resultados del estudio APPRECIATE"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "817"
        "paginaFinal" => "827"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "P&#46; Herranz, L&#46; Trasobares, A&#46; Mateu, E&#46; Mart&#237;nez, R&#46; Ruiz-Villaverde, O&#46; Baniandr&#233;s, J&#46; Mataix D&#237;az, N&#46; Jim&#233;nez-G&#243;mez, M&#46; Serra, D&#46;P&#46; Ruiz Genao, N&#46; Rivera, J&#46; Tercedor-S&#225;nchez, C&#46; Garcia, M&#46; Cordey, E&#46; Herrera-Acosta"
        "autores" => array:15 [
          0 => array:4 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz"
            "email" => array:1 [
              0 => "pedro.herranz@salud.madrid.org"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Trasobares"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Mateu"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Mart&#237;nez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Ruiz-Villaverde"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "O&#46;"
            "apellidos" => "Baniandr&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Mataix D&#237;az"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "N&#46;"
            "apellidos" => "Jim&#233;nez-G&#243;mez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Serra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "D&#46;P&#46;"
            "apellidos" => "Ruiz Genao"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "N&#46;"
            "apellidos" => "Rivera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Tercedor-S&#225;nchez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">l</span>"
                "identificador" => "aff0060"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Garcia"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0065"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Cordey"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">n</span>"
                "identificador" => "aff0070"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Herrera-Acosta"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">o</span>"
                "identificador" => "aff0075"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:15 [
          0 => array:3 [
            "entidad" => "Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Hospital Universitario Pr&#237;ncipe de Asturias&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Hospital Universitario Doctor Peset&#44; Valencia&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Hospital Llu&#237;s Alcany&#237;s X&#224;tiva&#44; Valencia&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Hospital Cl&#237;nico Universitario San Cecilio&#44; Granada&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Hospital Marina Baixa&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Hospital Ramon y Cajal&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Hospital Can Misses&#44; Illes Balears&#44; Espa&#241;a"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Fundaci&#243;n Hospital Alcorc&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Hospital de Mollet&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
          11 => array:3 [
            "entidad" => "Hospital Universitario Virgen de las Nieves&#44; Granada&#44; Espa&#241;a"
            "etiqueta" => "l"
            "identificador" => "aff0060"
          ]
          12 => array:3 [
            "entidad" => "Amgen Inc&#46;&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "m"
            "identificador" => "aff0065"
          ]
          13 => array:3 [
            "entidad" => "Amgen Inc&#46;&#44; Amgen &#40;Europe&#41; GmbH&#44; Rotkreuz&#44; Suiza"
            "etiqueta" => "n"
            "identificador" => "aff0070"
          ]
          14 => array:3 [
            "entidad" => "Vithas Xanit Iinternational Hospital&#44; M&#225;laga&#44; Espa&#241;a"
            "etiqueta" => "o"
            "identificador" => "aff0075"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain&#58; Results From the APPRECIATE Study"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0030"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1075
            "Ancho" => 1333
            "Tamanyo" => 171831
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">El uso de apremilast &#40;inhibidor oral de la fosfodiesterasa 4&#41; fue aprobado en Europa para tratar la psoriasis cr&#243;nica en placas de moderada a grave y la artritis psori&#225;sica en 2015<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#46; A partir de ensayos cl&#237;nicos&#44; apremilast demostr&#243; su eficacia y seguridad en pacientes con psoriasis de moderada a grave previamente tratados con terapias sist&#233;micas &#40;ESTEEM 1 y 2&#41;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3</span></a>&#44; sin terapia biol&#243;gica previa &#40;LIBERATE&#41;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> y sin terapia biol&#243;gica o sist&#233;mica previa &#40;UNVEIL&#41;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a>&#46; Posteriormente&#44; la efectividad mostrada en las series de pr&#225;ctica cl&#237;nica&#44; en perfiles de pacientes diferentes a los de los ensayos pivotales&#44; parece ser superior&#46; Por ello&#44; se consider&#243; conveniente ampliar el conocimiento sobre el uso y efectividad de apremilast en condiciones de pr&#225;ctica cl&#237;nica&#44; frente a los ensayos pivotales mencionados&#44; y generar datos sobre la satisfacci&#243;n obtenida por pacientes y dermat&#243;logos tras el uso de apremilast&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El estudio APPRECIATE &#40;NCT02740218&#41; tiene como objetivo describir las caracter&#237;sticas de los pacientes con psoriasis tratados con apremilast en la pr&#225;ctica cl&#237;nica habitual y evaluar las perspectivas de los pacientes y dermat&#243;logos cuando se inicia el tratamiento&#44; junto con los resultados y beneficios cl&#237;nicos obtenidos&#46; Los resultados de Alemania&#44; Austria&#44; Irlanda&#44; Reino Unido&#44; Suecia y Suiza fueron publicados recientemente<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a>&#46; En el presente trabajo se presentan los resultados de Espa&#241;a&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">M&#233;todos</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Dise&#241;o del estudio</span><p id="par0015" class="elsevierStylePara elsevierViewall">APPRECIATE es un estudio observacional&#44; retrospectivo&#44; transversal e internacional&#44; que recoge los resultados con apremilast seis meses despu&#233;s de iniciar tratamiento en la pr&#225;ctica cl&#237;nica habitual &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; El presente an&#225;lisis incluy&#243; los datos recopilados en 13 hospitales de Espa&#241;a&#44; donde el reclutamiento de pacientes se inici&#243; en mayo de 2018 y finaliz&#243; en noviembre de 2019&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Poblaci&#243;n</span><p id="par0020" class="elsevierStylePara elsevierViewall">Los pacientes elegibles eran adultos &#40;&#8805; 18 a&#241;os&#41; diagnosticados con psoriasis cr&#243;nica en placas que hab&#237;an iniciado tratamiento con apremilast 6 &#177; 1 meses antes de la inclusi&#243;n en el estudio&#46; Se invit&#243; a participar a todos los pacientes que cumpl&#237;an dichos criterios de forma consecutiva&#44; independientemente de que hubieran suspendido apremilast en el momento de su evaluaci&#243;n&#46; La inclusi&#243;n en el estudio no interfiri&#243; en ning&#250;n caso con la pr&#225;ctica habitual de cada dermat&#243;logo&#46; El &#250;nico criterio de exclusi&#243;n fue la participaci&#243;n de los pacientes en alg&#250;n ensayo cl&#237;nico&#46; El estudio se realiz&#243; de acuerdo con la Declaraci&#243;n de Helsinki y fue aprobado por los comit&#233;s &#233;ticos de los centros participantes&#46; Todos los participantes firmaron el consentimiento informado antes de la recopilaci&#243;n de datos&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Recopilaci&#243;n de datos</span><p id="par0025" class="elsevierStylePara elsevierViewall">El estudio se basa en una &#250;nica visita presencial a los 6 &#177; 1 meses del inicio de apremilast&#44; en la que se recogieron los datos de las historias cl&#237;nicas y de los cuestionarios completados por dermat&#243;logos y pacientes&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">De las historias cl&#237;nicas se recogieron los datos demogr&#225;ficos&#44; historial m&#233;dico&#44; comorbilidades&#44; gravedad de la enfermedad &#40;<span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#91;PASI&#93; y <span class="elsevierStyleItalic">Body Surface Area</span> &#91;BSA&#93;&#41;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a>&#44; manifestaciones cl&#237;nicas &#40;prurito&#44; fatiga&#44; u&#241;as&#44; cuero cabelludo&#44; palmoplantar&#44; psoriasis inversa genital y no genital&#44; pustulosis palmoplantar y artritis psori&#225;sica&#41;&#44; estado del tratamiento con apremilast &#40;fecha y motivos de discontinuaci&#243;n si aplica&#41;&#44; tratamientos previos para la psoriasis&#44; calidad de vida &#40;CdV&#44; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#91;DLQI&#93;&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> y acontecimientos adversos &#40;AAs&#41;&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Los dermat&#243;logos cumplimentaron tres cuestionarios de satisfacci&#243;n espec&#237;ficos del estudio que recog&#237;an informaci&#243;n sobre los motivos del uso de apremilast &#40;1&#41;&#44; los efectos del tratamiento sobre los s&#237;ntomas&#44; la tolerabilidad del tratamiento&#44; la efectividad de apremilast sobre las manifestaciones espec&#237;ficas de la psoriasis &#40;2&#41;&#44; el cumplimiento de las expectativas y el &#233;xito general &#40;3&#41;&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Los pacientes completaron tres cuestionarios&#58; <span class="elsevierStyleItalic">Patient Benefit Index</span> &#40;PBI&#41;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a>&#44; <span class="elsevierStyleItalic">Treatment Satisfaction Questionnaire for Medication</span> &#40;TSQM-9&#41;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a> y el cuestionario espec&#237;fico del estudio&#46; Dicho cuestionario recopil&#243; datos demogr&#225;ficos&#44; socioecon&#243;micos&#44; factores de estilo de vida y expectativas y experiencia con apremilast&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a> resume las principales herramientas de evaluaci&#243;n&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">An&#225;lisis estad&#237;stico</span><p id="par0050" class="elsevierStylePara elsevierViewall">Se analizaron los datos demogr&#225;ficos de los pacientes&#44; las caracter&#237;sticas de la enfermedad&#44; los resultados del tratamiento y los AAs mediante estad&#237;stica descriptiva&#46; Se calcularon los intervalos de confianza &#40;IC&#41; del 95&#37;&#46; Los valores ausentes no fueron imputados&#46; Los resultados se estratificaron seg&#250;n el estado de la terapia con apremilast&#58; en curso vs&#46; discontinuado&#46; Se calcularon las correlaciones entre las medidas de resultado&#46; Los an&#225;lisis estad&#237;sticos fueron realizados mediante el programa SAS versi&#243;n 9&#46;4&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Resultados</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Caracter&#237;sticas de la poblaci&#243;n</span><p id="par0055" class="elsevierStylePara elsevierViewall">En Espa&#241;a se invit&#243; a 86 pacientes a participar en el estudio APPRECIATE&#44; de los cuales 82 fueron incluidos en el estudio&#46; Finalmente&#44; 80 pacientes formaron parte de la poblaci&#243;n de seguridad y del conjunto de an&#225;lisis completo &#40;FAS&#41;&#59; dos pacientes &#40;2&#44;4&#37;&#41; fueron excluidos por no haber sido diagnosticados de psoriasis&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">En el momento de iniciar apremilast&#44; los pacientes presentaban una puntuaci&#243;n media basal para PASI y BSA &#40;desviaci&#243;n est&#225;ndar&#44; DE&#41; de 8&#44;3 &#40;5&#44;3&#41; y 11&#44;0 &#40;10&#44;8&#41;&#44; respectivamente&#46; Asimismo&#44; al inicio de apremilast&#44; la mayor&#237;a de los pacientes &#40;78&#44;6&#37;&#41; present&#243; una puntuaci&#243;n PASI &#60; 10 &#40;intensidad leve-moderada&#41; y la puntuaci&#243;n DLQI media &#40;DE&#41; fue 8&#44;9 &#40;6&#44;6&#41;&#44; mostrando un efecto moderado sobre la CdV &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; La principal sintomatolog&#237;a fue el prurito &#40;57&#44;5&#37;&#41; y la localizaci&#243;n m&#225;s frecuente fue el cuero cabelludo&#44; seguido de las u&#241;as &#40;42&#44;5&#37; y 33&#44;8&#37;&#44; respectivamente&#41;&#46; El 75&#44;0&#37; &#40;n &#61; 60&#41; de los pacientes presentaban comorbilidades asociadas &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; Al inicio del tratamiento con apremilast&#44; el 16&#44;3&#37; &#40;n &#61; 13&#41; y el 11&#44;3&#37; &#40;n &#61; 9&#41; de los pacientes recib&#237;an medicaci&#243;n para la ansiedad y la depresi&#243;n&#44; respectivamente&#46; La mayor&#237;a de los pacientes &#40;n &#61; 70&#59; 87&#44;5&#37;&#41; hab&#237;a recibido al menos un tratamiento sist&#233;mico previo para la psoriasis &#40;26 &#91;32&#44;5&#37;&#93; pacientes una terapia&#44; 25 &#91;31&#44;3&#37;&#93; pacientes dos terapias y 19 &#91;23&#44;8&#37;&#93; pacientes m&#225;s de dos terapias previas&#41; y seis &#40;7&#44;5&#37;&#41; manten&#237;an alg&#250;n otro tratamiento sist&#233;mico concomitante &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;&#46; La <a class="elsevierStyleCrossRef" href="#fig0010">figura 2</a> muestra las principales razones para considerar el tratamiento con apremilast&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Efectividad de apremilast</span><p id="par0065" class="elsevierStylePara elsevierViewall">El 58&#44;8&#37; &#40;n &#61; 47&#41; de los pacientes evaluados continuaban en tratamiento con apremilast despu&#233;s de seis meses&#46; Los pacientes que suspendieron el f&#225;rmaco lo utilizaron durante una media &#40;DE&#41; de 103&#44;5 &#40;64&#44;3&#41; d&#237;as&#46; Los principales motivos de discontinuaci&#243;n fueron la falta de eficacia &#40;n &#61; 13&#47;80&#59; 16&#44;3&#37;&#41; y motivos de seguridad&#47;tolerabilidad &#40;n &#61; 16&#47;80&#59; 20&#44;0&#37;&#41;&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">En los pacientes que continuaban con apremilast a los seis meses en los que se dispon&#237;a de las diferentes puntuaciones al inicio y al seguimiento&#44; la media de la puntuaci&#243;n PASI al seguimiento &#40;n &#61; 30&#47;47&#59; 63&#44;8&#37;&#41; fue de 3&#44;4 &#40;IC 95&#37;&#58; 2&#44;1-4&#44;7&#41;&#44; lo que supone una mejor&#237;a del 54&#44;8&#37; &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; El objetivo PASI75 fue alcanzado por el 36&#44;7&#37; &#40;n &#61; 11&#47;30&#41; de los pacientes&#44; y el 80&#44;0&#37; &#40;n &#61; 24&#47;30&#41; alcanz&#243; PASI&#60; 5 &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; De los pacientes que al inicio del tratamiento presentaban PASI&#60; 10 &#40;n &#61; 23&#41; el 26&#44;1&#37; &#40;n &#61; 6&#47;23&#59; IC 95&#37;&#58; 10&#44;2-48&#44;4&#37;&#41; alcanz&#243; PASI75 y el 78&#44;3&#37; &#40;n &#61; 18&#47;23&#41; PASI&#60; 5&#59; entre los pacientes con PASI&#8805; 10 al inicio &#40;n &#61; 7&#41;&#44; se alcanz&#243; PASI75 en cinco pacientes y PASI&#60; 5 en seis pacientes&#46; La media &#40;IC 95&#37;&#41; de la puntuaci&#243;n DLQI al seguimiento &#40;n &#61; 12&#47;47&#59; 25&#44;5&#37;&#41; fue de 2&#44;2 &#40;0&#44;7-3&#44;6&#41;&#44; lo que supone una mejor&#237;a media de 6&#44;2 puntos &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46; Los siete pacientes con DLQI &#8805; 4 al inicio del tratamiento alcanzaron una mejor&#237;a &#8805; 4 puntos a los seis meses&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Satisfacci&#243;n del dermat&#243;logo con apremilast</span><p id="par0075" class="elsevierStylePara elsevierViewall">Seg&#250;n la evaluaci&#243;n por los dermat&#243;logos&#44; el 73&#44;8&#37; &#40;n &#61; 59&#41; de los pacientes presentaron mejor&#237;a en las valoraciones de aclaramiento general de la psoriasis&#44; el 61&#44;3&#37; &#40;n &#61; 49&#41; bienestar general y el 56&#44;3&#37; &#40;n &#61; 45&#41; en el objetivo de alcanzar una vida diaria normal&#46; Entre los pacientes que al inicio mostraban s&#237;ntomas y manifestaciones espec&#237;ficas de la psoriasis&#44; los dermat&#243;logos confirmaron una mejor&#237;a del prurito en el 80&#44;4&#37; &#40;37&#47;46&#41;&#44; 67&#44;6&#37; &#40;23&#47;34&#41; de las manifestaciones en cuero cabelludo&#44; 63&#44;0&#37; &#40;17&#47;27&#41; en la afectaci&#243;n ungueal y 55&#44;0&#37; &#40;11&#47;20&#41; en las lesiones palmoplantares&#46; Los dermat&#243;logos indicaron que los resultados obtenidos fueron superiores a sus expectativas en la mitad de los pacientes tratados &#40;50&#44;0&#37;&#59; n &#61; 40&#41;&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Satisfacci&#243;n del paciente con apremilast</span><p id="par0080" class="elsevierStylePara elsevierViewall">La puntuaci&#243;n PBI media &#40;DE&#41; para la poblaci&#243;n total fue 2&#44;2 &#40;1&#44;2&#41; y el 83&#44;2&#37; &#40;n &#61; 64&#41; de los pacientes alcanz&#243; PBI &#8805; 1 &#40;beneficio cl&#237;nicamente significativo&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>&#41;&#46; En los pacientes que se manten&#237;an con apremilast&#44; la media &#40;DE&#41; de la puntuaci&#243;n PBI fue 2&#44;8 &#40;0&#44;8&#41; y el 100&#44;0&#37; &#40;n &#61; 45&#41; alcanz&#243; PBI &#8805; 1 &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0085" class="elsevierStylePara elsevierViewall">En los pacientes que continuaban con apremilast&#44; la puntuaci&#243;n media global &#40;DE&#41; de satisfacci&#243;n con el tratamiento &#40;cuestionario TSQM-9&#41; fue 66&#44;6 &#40;22&#44;9&#41;&#44; 76&#44;6 &#40;21&#44;0&#41; y 70&#44;5 &#40;21&#44;5&#41; para las subescalas de efectividad&#44; conveniencia y satisfacci&#243;n global&#44; respectivamente &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>&#41;&#46; En este mismo grupo de pacientes&#44; se observ&#243; una reducci&#243;n de los s&#237;ntomas de psoriasis durante el primer mes de tratamiento en el 48&#44;9&#37; &#40;n &#61; 23&#41;&#44; y el 59&#44;6&#37; &#40;n &#61; 28&#41; consider&#243; que apremilast le permit&#237;a llevar una vida cotidiana normal&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Correlaci&#243;n de las evaluaciones cl&#237;nicas&#44; expectativas y beneficios reportados por dermat&#243;logos y pacientes</span><p id="par0090" class="elsevierStylePara elsevierViewall">La correlaci&#243;n entre el cambio porcentual respecto al valor basal del PASI y el beneficio del tratamiento &#40;puntuaci&#243;n del PBI global&#41; reportado por los pacientes mostr&#243; una correlaci&#243;n negativa muy baja &#40;coeficiente de correlaci&#243;n &#61; -0&#44;14299&#41;&#44; lo que significa que no hab&#237;a mucha correlaci&#243;n&#44; es decir&#44; que la respuesta cut&#225;nea no fue suficiente para explicar el beneficio del paciente con el tratamiento &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>&#41;&#46; Por el contrario&#44; la evaluaci&#243;n de los dermat&#243;logos sobre el &#233;xito general de apremilast y la percepci&#243;n de los pacientes sobre el beneficio del tratamiento &#40;puntuaci&#243;n del PBI global&#41; mostr&#243; una correlaci&#243;n positiva alta &#40;coeficiente de correlaci&#243;n&#61; 0&#44;63629&#41;&#46; Los casos en los que los dermat&#243;logos indicaron que sus expectativas se alcanzaron o superaron coincidieron con la percepci&#243;n de los pacientes de un alto beneficio &#40;PBI &#8805; 3&#41;&#44; y viceversa&#46;</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">En la <a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a> se muestran los niveles de satisfacci&#243;n de dermat&#243;logos y pacientes respecto al efecto del tratamiento con apremilast sobre los s&#237;ntomas&#46; Concretamente&#44; la satisfacci&#243;n de los pacientes que continuaban en tratamiento con apremilast fue del 63&#44;8&#37; en la respuesta r&#225;pida&#44; 66&#44;0&#37; en la respuesta mantenida&#44; 70&#44;2&#37; en la reducci&#243;n del prurito&#44; 70&#44;2&#37; en la mejor&#237;a del estado de &#225;nimo y 72&#44;3&#37; en la sensaci&#243;n de bienestar general&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Seguridad</span><p id="par0100" class="elsevierStylePara elsevierViewall">Se registraron un total de 80 AAs en 45 pacientes &#40;56&#44;3&#37;&#41;&#46; En la gran mayor&#237;a de estos casos &#40;n &#61; 44 &#91;55&#44;0&#37;&#93;&#41;&#44; dichos AAs se relacionaron con el tratamiento&#44; y en 18 pacientes &#40;22&#44;5&#37;&#41; condujeron a la retirada de apremilast&#46; Los AAs reportados con mayor frecuencia fueron diarrea &#40;27&#44;5&#37;&#41; y n&#225;useas &#40;18&#44;8&#37;&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">tabla 5</a>&#41;&#46; Tres pacientes sufrieron insomnio &#40;uno de estos casos&#44; en tratamiento previo por ansiedad&#41;&#46; No se registraron AA graves&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Discusi&#243;n</span><p id="par0105" class="elsevierStylePara elsevierViewall">El estudio observacional APPRECIATE demuestra que los pacientes tratados con apremilast en condiciones de pr&#225;ctica habitual en Espa&#241;a&#44; presentaban caracter&#237;sticas diferentes a las observadas en los ensayos cl&#237;nicos<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5</span></a>&#58; afectaci&#243;n cut&#225;nea m&#225;s moderada &#40;puntuaci&#243;n PASI media &#61; 8&#44;3 con puntuaciones &#60; 10 en el 78&#44;6&#37; de los pacientes&#41; junto a impacto sustancial en la CdV &#40;puntuaci&#243;n DLQI media &#61; 8&#44;9&#41;&#46; Publicaciones previas &#40;incluida la de la poblaci&#243;n europea del estudio APPRECIATE&#41; ya hab&#237;an confirmado esta tendencia a tratar pacientes menos graves&#44; a pesar de que asocian un elevado impacto en la CdV<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5&#44;6&#44;11&#8211;16</span></a>&#46; Esta observaci&#243;n sugiere que apremilast puede satisfacer una necesidad de tratamiento en pacientes con una afecci&#243;n cut&#225;nea m&#225;s moderada&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Aunque los &#237;ndices PASI y DLQI son herramientas usadas com&#250;nmente para evaluar la gravedad de la enfermedad y la eficacia del tratamiento&#44; en el presente estudio su uso s&#243;lo pudo ser recogido&#44; al inicio del tratamiento y al seguimiento&#44; en el 37&#44;5 y 15&#44;0&#37; de los pacientes&#44; respectivamente&#46; Estos datos sugieren que estas escalas no se usan de manera consistente en la pr&#225;ctica diaria&#44; por lo que parece necesario mejorar la evaluaci&#243;n de las necesidades de los pacientes y la efectividad del tratamiento m&#225;s all&#225; de las medidas tradicionales&#46; En este sentido&#44; el presente an&#225;lisis muestra una baja correlaci&#243;n negativa entre el porcentaje de cambio en PASI a los seis meses de tratamiento y el beneficio global del tratamiento reportado por los pacientes &#40;PBI&#41;&#44; lo que sugiere que la mejor&#237;a de las lesiones visibles no fue suficiente para explicar el beneficio del paciente&#46; Adem&#225;s&#44; los pacientes tambi&#233;n reportaron su satisfacci&#243;n con la respuesta r&#225;pida y mantenida a apremilast&#44; as&#237; como con la reducci&#243;n del prurito&#44; la mejor&#237;a del estado de &#225;nimo y la sensaci&#243;n de bienestar general&#46; Dermat&#243;logos y pacientes reportaron una satisfacci&#243;n similar con apremilast&#46; Adem&#225;s&#44; la evaluaci&#243;n de los dermat&#243;logos sobre el &#233;xito general de apremilast en el logro de las expectativas y la percepci&#243;n de los pacientes sobre el beneficio obtenido mostraron una correlaci&#243;n positiva alta&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Por otra parte&#44; el grupo de pacientes que mantuvieron tratamiento con apremilast durante seis meses mostraron mejor&#237;a en PASI &#40;reducci&#243;n de 5&#44;5 puntos&#41;&#44; BSA &#40;reducci&#243;n del 10&#44;6&#37; de la superficie corporal&#41;&#44; DLQI &#40;reducci&#243;n de 6&#44;2 puntos&#41;&#44; PBI &#40;todos los pacientes alcanzaron PBI &#8805; 1&#44; valor considerado como beneficio cl&#237;nicamente significativo&#41;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a> y TSQM-9 &#40;satisfacci&#243;n global &#61; 70&#44;5 puntos&#41;&#46; Los valores alcanzados para PASI &#40;3&#44;4&#41;&#44; BSA &#40;2&#44;6&#41; y DLQI &#40;2&#44;2&#41; fueron consistentes con los observados en el estudio del Grupo Espa&#241;ol de Psoriasis &#40;GPs&#41; &#40;3&#44;6&#59; 3&#44;1 &#91;semana 12&#93;&#47;2&#44;5 &#91;semana 52&#93;&#59; 5&#44;2 &#91;semana 12&#93;&#47;2&#44;3 &#91;semana 52&#93;&#44; respectivamente&#41;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">16</span></a> y en el an&#225;lisis intermedio del estudio APPROPRIATE &#40;2&#44;6&#59; 3&#44;7 y 53&#37; valores de 0-1&#44; respectivamente&#41;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">17</span></a>&#46; En el estudio APPRECIATE multinacional&#44; los valores alcanzados &#40;PASI &#61; 4&#44;6&#59; BSA &#61; 10&#44;9&#59; DLQI &#61; 5&#44;7&#41; fueron ligeramente m&#225;s elevados&#44; pero se debe considerar que los valores de partida eran tambi&#233;n mayores &#40;PASI &#61; 12&#44;5&#59; BSA &#61; 25&#44;4&#59; DLQI &#61; 13&#44;4&#41;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a>&#46; La persistencia a los seis meses fue del 58&#44;8&#37; en este estudio frente al 72&#44;3&#37; observado en el estudio APPRECIATE multinacional&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">El perfil de seguridad de apremilast confirm&#243; el ya observado en los ensayos cl&#237;nicos<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5</span></a>&#46; Al igual que en otros estudios de pr&#225;ctica cl&#237;nica&#44; la proporci&#243;n de AAs fue menor que la de los ensayos &#40;47-59 vs&#46; 67-79&#37;&#44; respectivamente&#41; pero&#44; por el contrario la proporci&#243;n de pacientes que discontinuaron apremilast debido a AAs fue mayor &#40;16-23 vs&#46; 6&#44;6-7&#44;3&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2&#44;3&#44;5&#44;16&#44;18&#44;19</span></a>&#46; Pese a que la ficha t&#233;cnica de apremilast advierte sobre su uso cauteloso en pacientes con depresi&#243;n<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#44; el 11&#44;3&#37; de los pacientes tratados en este estudio estaban recibiendo tratamiento antidepresivo cuando iniciaron apremilast&#59; ninguno de estos pacientes present&#243; AA relacionados con trastornos psiqui&#225;tricos&#46; Por otra parte&#44; en este estudio no se han reportado infecciones en v&#237;as respiratorias superiores&#44; AA reportado con una frecuencia del 8&#44;4&#37; y principalmente de intensidad leve en la ficha t&#233;cnica<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a>&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">En este estudio se incluyeron todos los pacientes consecutivos que pudieron ser contactados seis meses &#40;&#177; 1 mes&#41; despu&#233;s del inicio del tratamiento &#40;pudiendo pacientes haber completado o no los seis meses de tratamiento con apremilast&#41; con la finalidad de minimizar el sesgo en la selecci&#243;n de los pacientes&#46; No obstante&#44; este estudio presenta algunas limitaciones inherentes a su dise&#241;o retrospectivo&#44; su corto periodo de seguimiento y las condiciones de pr&#225;ctica cl&#237;nica&#44; as&#237; como la inexistencia de un grupo control o la disponibilidad de datos en algunos pacientes&#46; El hecho que haya un porcentaje bajo de pacientes con valores PASI y DLQI disponibles puede haber influenciado en los an&#225;lisis realizados&#46; Se reconoce un potencial sesgo positivo de selecci&#243;n porque los pacientes con experiencia positiva con apremilast pudieron ser m&#225;s propensos a aceptar participar en el estudio&#46; Finalmente&#44; como los cuestionarios fueron rellenados retrospectivamente&#44; no podemos descartar el sesgo de memoria&#44; aunque la duraci&#243;n del estudio &#40;seis meses&#41; fue especialmente escogida para minimizar este riesgo&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Conclusiones</span><p id="par0130" class="elsevierStylePara elsevierViewall">El estudio APPRECIATE muestra que los pacientes que iniciaron apremilast en la pr&#225;ctica cl&#237;nica en Espa&#241;a presentaban una afectaci&#243;n cut&#225;nea menor que aquellos reclutados en ensayos cl&#237;nicos&#46; Aun as&#237;&#44; se confirma un impacto inesperadamente elevado en la CdV de estos pacientes&#46; Esto sugiere que&#44; a la hora de evaluar la importancia real de la enfermedad&#44; deben considerarse y medirse otros factores&#44; adem&#225;s del grado de afectaci&#243;n de la piel&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Los resultados del estudio muestran que a los seis meses del inicio de apremilast&#44; se observaron mejor&#237;as en las evaluaciones globales de la gravedad de la enfermedad &#40;PASI75 36&#44;7&#37;&#41;&#44; en la CdV &#40;DLQI medio se redujo m&#225;s de 6 puntos&#41; y en la satisfacci&#243;n de los pacientes que continuaban en tratamiento con apremilast &#40;63&#44;8&#37; en la respuesta r&#225;pida&#44; 66&#44;0&#37; en la respuesta mantenida&#44; 70&#44;2&#37; en la reducci&#243;n del prurito&#44; 70&#44;2&#37; en la mejor&#237;a del estado de &#225;nimo y 72&#44;3&#37; en la sensaci&#243;n de bienestar general&#41;&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Finalmente&#44; los resultados de este estudio resaltan la necesidad de definir la gravedad de la psoriasis de una manera m&#225;s completa&#44; incorporando medidas centradas en el paciente a la medici&#243;n de las escalas tradicionales&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Financiaci&#243;n</span><p id="par0145" class="elsevierStylePara elsevierViewall">Este estudio ha sido financiado por Celgene&#46; Amgen adquiri&#243; los derechos de Otezla&#174; &#40;apremilast&#41; en todo el mundo el 21 de noviembre de 2019&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Los investigadores cualificados pueden solicitar datos de estudios cl&#237;nicos de Amgen&#46; Los detalles completos est&#225;n disponibles en <a href="http://www.amgen.com/datasharing">http&#58;&#47;&#47;www&#46;amgen&#46;com&#47;datasharing</a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Conflicto de intereses</span><p id="par0155" class="elsevierStylePara elsevierViewall">Pedro Herranz&#58; investigador&#47;asesor&#47;conferenciante de AbbVie&#44; Almirall&#44; Amgen&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sandoz&#44; Sanofi y UCB Pharma&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Lidia Trasobares&#58; investigadora y&#47;o conferenciante de AbbVie&#44; Almirall&#44; Amgen&#44; Celgene&#44; Janssen&#44; LEO Pharma&#44; Meda y Novartis&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Almudena Mateu&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Esperanza Mart&#237;nez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">Ricardo Ruiz Villaverde conferenciante y&#47;o asesor de AbbVie&#44; Amgen&#44; Celgene&#44; LEO Pharma&#44; Lilly&#44; MSD&#44; Novartis y UCB Pharma&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Ofelia Baniandr&#233;s&#58; asesora y&#47;o conferenciante de AbbVie&#44; Celgene&#44; LEO Pharma&#44; Lilly MSD&#44; Novartis&#44; Janssen y Pfizer&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">Javier Mataix D&#237;az&#58; no declara ning&#250;n conflicto de intereses&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Natalia Jim&#233;nez G&#243;mez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">Marta Serra&#58; conferenciante de AbbVie&#44; Almirall&#44; Celgene&#44; Janssen&#44; LEO Pharma y Lilly&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Diana Patricia Ruiz Genao asesora y&#47;o conferenciante honoraria de AbbVie&#44; Amgen&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Novartis y Pfizer&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">Noelia Rivera&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">Jes&#250;s Tercedor S&#225;nchez&#58; no declaran conflictos de inter&#233;s&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">Carmen Garc&#237;a&#58; anterior empleada de Amgen&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Myriam Cordey&#58; empleados de Amgen &#40;Europe&#41; GmbH&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Enrique Herrera Acosta&#58; no declaran conflictos de inter&#233;s&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1581253"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1581251"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Antecedentes y objetivos"
            ]
            1 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "M&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1423454"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1581252"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Background and objectives"
            ]
            1 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0045"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1423455"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Dise&#241;o del estudio"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Poblaci&#243;n"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Recopilaci&#243;n de datos"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "An&#225;lisis estad&#237;stico"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Resultados"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Caracter&#237;sticas de la poblaci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Efectividad de apremilast"
            ]
            2 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Satisfacci&#243;n del dermat&#243;logo con apremilast"
            ]
            3 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Satisfacci&#243;n del paciente con apremilast"
            ]
            4 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Correlaci&#243;n de las evaluaciones cl&#237;nicas&#44; expectativas y beneficios reportados por dermat&#243;logos y pacientes"
            ]
            5 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Seguridad"
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Discusi&#243;n"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conclusiones"
        ]
        10 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Financiaci&#243;n"
        ]
        11 => array:2 [
          "identificador" => "sec0085"
          "titulo" => "Conflicto de intereses"
        ]
        12 => array:2 [
          "identificador" => "xack558531"
          "titulo" => "Agradecimientos"
        ]
        13 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2021-02-18"
    "fechaAceptado" => "2021-05-09"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1423454"
          "palabras" => array:4 [
            0 => "Apremilast"
            1 => "Psoriasis"
            2 => "Pr&#225;ctica cl&#237;nica"
            3 => "Beneficios terap&#233;uticos"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1423455"
          "palabras" => array:4 [
            0 => "Apremilast"
            1 => "Psoriasis"
            2 => "Clinical practice"
            3 => "Therapeutic benefits"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Antecedentes y objetivos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Es conveniente ampliar el conocimiento del manejo de apremilast en pr&#225;ctica cl&#237;nica&#46; El estudio APPRECIATE &#40;NCT02740218&#41; pretende describir las caracter&#237;sticas de pacientes con psoriasis tratados con apremilast&#44; evaluar sus perspectivas y las de sus dermat&#243;logos&#44; y los resultados obtenidos en la pr&#225;ctica cl&#237;nica espa&#241;ola&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">M&#233;todos</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Estudio observacional&#44; retrospectivo&#44; transversal y multic&#233;ntrico en pacientes con psoriasis cr&#243;nica en placas&#44; a los que se visit&#243; seis &#40;&#177; 1&#41; meses despu&#233;s de iniciar apremilast&#46; Los datos se obtuvieron de las historias cl&#237;nicas y cuestionarios realizados por pacientes y dermat&#243;logos&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Resultados</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Se evaluaron 80 pacientes&#44; al iniciar apremilast presentaban <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; medio &#40;desviaci&#243;n est&#225;ndar&#44; DE&#41; &#61; 8&#44;3 &#40;5&#44;3&#41; y <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; medio &#40;DE&#41; &#61; 8&#44;9 &#40;6&#44;6&#41;&#46; A los seis meses&#44; el 58&#44;8&#37; &#40;n &#61; 47&#41; continuaba con apremilast &#40;discontinuaciones&#58; falta de eficacia &#91;16&#44;3&#37;&#93;&#44; seguridad&#47;tolerabilidad &#91;20&#44;0&#37;&#93;&#41;&#46; En pacientes que continuaban en tratamiento&#44; el PASI75 fue alcanzado por el 36&#44;7&#37;&#59; la puntuaci&#243;n DLQI media &#40;IC 95&#37;&#41; fue 2&#44;2 &#40;0&#44;7-3&#44;6&#41; y <span class="elsevierStyleItalic">Patient Benefit Index</span> medio &#40;DE&#41; 2&#44;8 &#40;0&#44;8&#41;&#46; El cumplimiento de las expectativas de los dermat&#243;logos se correlacion&#243; con los beneficios descritos por los pacientes &#40;r &#61; 0&#44;636&#41;&#46; El 56&#44;3&#37; report&#243; acontecimientos adversos &#40;diarrea y n&#225;useas los m&#225;s frecuentes&#41;&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusiones</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Los pacientes que recibieron apremilast durante seis meses en la pr&#225;ctica cl&#237;nica en Espa&#241;a reportaron una mejor&#237;a en su calidad de vida &#40;DLQI medio se redujo m&#225;s de seis puntos&#41; y en la gravedad de la enfermedad &#40;PASI75 alcanzado por m&#225;s de un tercio de los pacientes&#41;&#44; a pesar de presentar una afectaci&#243;n cut&#225;nea menor que aquellos pacientes incluidos en ensayos cl&#237;nicos&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Antecedentes y objetivos"
          ]
          1 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "M&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Background and objectives</span><p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">It is necessary to expand the knowledge in the use of apremilast in clinical practice&#46; The APPRECIATE study &#40;NCT02740218&#41; aims to describe the characteristics of patients with psoriasis treated with apremilast&#44; to evaluate their perspectives and those of dermatologists&#44; as well as the outcomes obtained in clinical practice in Spain&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Methods</span><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Observational&#44; retrospective&#44; cross-sectional&#44; multicenter study of patients with chronic plaque psoriasis who could be contacted 6 &#40;&#177;1&#41; months after apremilast initiation&#46; The data were obtained from medical records and questionnaires from patients and physicians&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Results</span><p id="spar0125" class="elsevierStyleSimplePara elsevierViewall">A total of 80 patients were evaluated&#59; at apremilast onset&#44; they showed mean &#40;standard deviation&#44; SD&#41; Psoriasis Area and Severity Index &#40;PASI&#41; &#61; 8&#46;3 &#40;5&#46;3&#41;&#44; mean &#40;SD&#41; Dermatology Life Quality Index &#40;DLQI&#41; &#61; 8&#46;9 &#40;6&#46;6&#41;&#46; At six months&#44; 58&#46;8&#37; &#40;n&#61;47&#41; of patients continued apremilast treatment &#40;discontinuations due to lack of efficacy &#91;16&#46;3&#37;&#93;&#44; safety&#47;tolerability &#91;20&#46;0&#37;&#93;&#41;&#46; In patients continuing treatment&#44; PASI75 was achieved by 36&#46;7&#37; of patients&#59; mean &#40;95&#37; CI&#41; DLQI score was 2&#46;2 &#40;0&#46;7-3&#46;6&#41; and mean &#40;SD&#41; Patient Benefit Index score was 2&#46;8 &#40;0&#46;8&#41;&#46; Compliance with physicians&#8217; expectations was correlated with benefits reported by patients &#40;r&#61;0&#46;636&#41;&#46; Adverse events were reported by 56&#46;3&#37; of patients &#40;the most common were diarrhoea and nausea&#41;&#46;</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Conclusions</span><p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">Patients receiving apremilast for 6 months in Spanish clinical practice&#44; reported substantial improvements in their quality of life &#40;mean DLQI reduced by more than 6 points&#41; and disease severity &#40;PASI75 achieved by over one-third of patients&#41;&#44; despite less skin involvement than patients who enrolled in clinical trials&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Background and objectives"
          ]
          1 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0045"
            "titulo" => "Conclusions"
          ]
        ]
      ]
    ]
    "multimedia" => array:11 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2735
            "Ancho" => 2925
            "Tamanyo" => 417255
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Dise&#241;o del estudio&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1429
            "Ancho" => 2508
            "Tamanyo" => 156315
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Principales razones para considerar el tratamiento con apremilast&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2154
            "Ancho" => 2925
            "Tamanyo" => 238175
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Porcentaje de pacientes por categor&#237;as de la puntuaci&#243;n global PBI &#40;<span class="elsevierStyleItalic">Patient Benefit Index</span>&#41; a los seis &#40;&#177;1&#41; meses de iniciar tratamiento con apremilast&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figura 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 2334
            "Ancho" => 2925
            "Tamanyo" => 261868
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Calificaciones de satisfacci&#243;n de los pacientes mediante el <span class="elsevierStyleItalic">Treatment Satisfaction Questionnaire for Medication</span> &#40;TSQM-9&#41;&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 1940
            "Ancho" => 2925
            "Tamanyo" => 181706
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Correlaci&#243;n entre el cambio porcentual respecto al valor inicial en el <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; y el beneficio global reportado por el paciente mediante el <span class="elsevierStyleItalic">Patient Benefit Index</span> &#40;PBI&#41;&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#205;ndice o cuestionario&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Objetivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Puntuaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Body Surface Area &#40;BSA&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medir la superficie corporal afectada por las lesiones de psoriasis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leve&#58; &#60; 3&#37; de la superficie&#59; Moderada&#58; 3-10&#37;&#59; Grave&#58; &#62; 10&#37;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis Area and Severity Index &#40;PASI&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar severidad de cada lesi&#243;n &#40;en base a eritema&#44; infiltraci&#243;n y descamaci&#243;n&#41; y el &#225;rea que afecta &#40;cabeza&#44; tronco&#44; extremidades superiores e inferiores&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leve&#58; 0-5&#59; Moderada&#58; 5-10&#59; Grave&#58; &#62; 10&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Physician&#39;s Global Assessment &#40;PGA&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar la intensidad de las lesiones&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Blanqueada&#58; 0&#59; Casi blanqueada&#58; 1&#59; Leve&#58; 2&#59; Leve a moderada&#58; 3&#59; Moderada&#58; 4&#59; Moderada a grave&#58; 5&#59; Grave&#58; 6&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatology Life Quality Index &#40;DLQI&#41;<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valorar el efecto de la enfermedad en la calidad de vida&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sin efecto&#58; 0-1&#59; Efecto m&#237;nimo&#58; 2-5&#59; Efecto moderado&#58; 6-10&#59; Muy grande&#58; 11-20&#59; Extremadamente grande&#58; 21-30&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Patient Benefit Index &#40;PBI&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Valorar el beneficio que aporta el tratamiento desde la perspectiva del paciente en base a un cuestionario sobre las necesidades terap&#233;uticas del paciente y otro sobre el beneficio alcanzado por el tratamiento&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Sin beneficio&#58; 0&#59; Beneficio m&#237;nimo&#58; 1&#59; Beneficio m&#225;ximo&#58; 4&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Treatment Satisfaction Questionnaire for Medication &#40;TSQM-9&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Valorar la satisfacci&#243;n con el tratamiento en t&#233;rminos de efectividad&#44; conveniencia y satisfacci&#243;n global&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">De 0-100&#44; donde 100 representa la m&#225;xima satisfacci&#243;n&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708763.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Fuente&#58; Chalmers<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a></p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Fuente&#58; Finlay et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Fuente&#58; Feuerhahn et al&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a></p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Fuente&#58; Atkinson et al&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a></p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Principales herramientas de evaluaci&#243;n utilizadas</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pacientes &#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Datos demogr&#225;ficos</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Edad &#40;a&#241;os&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#44;4 &#40;15&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hombres&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Peso &#40;kg&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&#44;4 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#44;8 &#40;5&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fumador actualmente&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;30&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Consumidor de alcohol&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;38&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Caracter&#237;sticas de la enfermedad</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Tiempo desde el diagn&#243;stico &#40;a&#241;os&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#44;9 &#40;12&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#40;n &#61; 56&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;3 &#40;5&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#60; 10&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;78&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PASI &#8805; 10&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;21&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BSA &#40;n &#61; 42&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&#44;0 &#40;10&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PGA &#40;n &#61; 73&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;7 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>DLQI &#40;n &#61; 30&#41;&#44; media &#40;DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;9 &#40;6&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pacientes con alguna comorbilidad&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60 &#40;75&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Comorbilidades &#40;&#62; 5&#37; de pacientes&#41;&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>S&#237;ndrome metab&#243;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28 &#40;35&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hipertensi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Depresi&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Localizaci&#243;n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cuero cabelludo&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;42&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>U&#241;as&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;33&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Genital&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;13&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psoriasis palmoplantar&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;25&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pustulosis palmoplantar&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;6&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Inversa no genital&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;6&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">S&#237;ntomatolog&#237;a de la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prurito&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;57&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fatiga&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;13&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tratamientos previos para la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sist&#233;mico convencional<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">&#8225;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63 &#40;78&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fototerapia<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">&#8224;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;32&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Biol&#243;gico<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">&#167;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Razones para finalizar los tratamientos previos</span><a class="elsevierStyleCrossRef" href="#tblfn0040">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Falta de eficacia&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52 &#40;65&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Efectos adversos&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Coste&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Medicaci&#243;n concomitante para la psoriasis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UVA&#47;UVB&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;3&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Glucocorticoides&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Metotrexato&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>nbUVB&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;1&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708761.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Tratamiento sist&#233;mico convencional incluy&#243; metotrexato &#40;n &#61; 38&#59; 47&#44;5&#37;&#41;&#44; acitretina &#40;n &#61; 25&#59; 31&#44;3&#37;&#41;&#44; retinoides &#40;n &#61; 16&#59; 20&#44;0&#37;&#41;&#44; ciclosporina &#40;n &#61; 14&#59; 17&#44;5&#37;&#41;&#44; alitretino&#237;na &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; &#225;cido fum&#225;rico &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; sulfasalazina &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Fototerapia incluy&#243; UVA&#47;UVB &#40;n &#61; 17&#59; 21&#44;3&#37;&#41;&#44; psoraleno &#43; UVA &#40;n &#61; 7&#59; 8&#44;8&#37;&#41;&#44; nbUVB &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Tratamiento biol&#243;gico incluy&#243; etanercept &#40;n &#61; 5&#59; 6&#44;3&#37;&#41;&#44; ustekinumab &#40;n &#61; 5&#59; 6&#44;3&#37;&#41;&#44; secukinumab &#40;n &#61; 4&#59; 5&#44;0&#37;&#41;&#44; adalimumab &#40;n &#61; 3&#59; 3&#44;8&#37;&#41;&#44; ixekizumab &#40;n &#61; 2&#59; 2&#44;5&#37;&#41;&#44; efalizumab &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#44; infliximab &#40;n &#61; 1&#59; 1&#44;3&#37;&#41;&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">Se pod&#237;a indicar m&#225;s de una raz&#243;n para cada paciente&#46;</p> <p class="elsevierStyleNotepara" id="npar0045">BSA&#58; Body Surface Area&#59; DE&#58; desviaci&#243;n est&#225;ndar&#59; DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; IMC&#58; &#237;ndice de masa corporal&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">Physician&#39;s Global Assessment</span>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Datos demogr&#225;ficos y caracter&#237;sticas de la enfermedad al inicio de apremilast</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Evaluaci&#243;n cl&#237;nica<a class="elsevierStyleCrossRef" href="#tblfn0045">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Al inicio de apremilast&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">A los 6 meses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cambio absoluto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI &#40;n &#61; 30&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;9 &#40;6&#44;4-11&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;4 &#40;2&#44;1-4&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-5&#44;5 &#40;-8&#44;3- -2&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI75 &#40;n &#61; 30&#41;&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;36&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PASI&#60; 5 &#40;n &#61; 30&#41;&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;16&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 &#40;80&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BSA &#40;n &#61; 20&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#44;3 &#40;7&#44;0-19&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;6 &#40;1&#44;6-3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10&#44;6 &#40;-16&#44;8- -4&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PGA &#40;n &#61; 44&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;8 &#40;2&#44;4-3&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#44;9 &#40;1&#44;6-2&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-0&#44;9 &#40;-1&#44;2- -0&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">DLQI &#40;n &#61; 12&#41;&#44; media &#40;IC 95&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;3 &#40;3&#44;5-13&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;2 &#40;0&#44;7-3&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-6&#44;2 &#40;-10&#44;2- -2&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708765.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Datos de pacientes que a los seis meses continuaban en tratamiento con apremilast en los que se ten&#237;a el dato al inicio y al seguimiento&#46;</p> <p class="elsevierStyleNotepara" id="npar0055">BSA&#58; Body Surface Area&#59; DLQI&#58; <span class="elsevierStyleItalic">Dermatology Life Quality Index</span>&#59; IC&#44; intervalo de confianza&#59; NA&#58; no aplica&#59; PASI&#58; <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span>&#59; PGA&#58; <span class="elsevierStyleItalic">Physician&#39;s Global Assessment</span>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Evoluci&#243;n de las evaluaciones cl&#237;nicas</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Beneficios<a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los dermat&#243;logos&#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los pacientes&#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Satisfacci&#243;n de los pacientes que contin&#250;an en tratamiento&#40;n &#61; 47&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta r&#225;pida&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">41 &#40;51&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30 &#40;63&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respuesta mantenida&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49 &#40;61&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;45&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;66&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n notable de la psoriasis en placa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50 &#40;62&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32 &#40;40&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;53&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aclaramiento de &#225;reas espec&#237;ficas<a class="elsevierStyleCrossRef" href="#tblfn0055"><span class="elsevierStyleSup">&#167;</span></a>&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42 &#40;52&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40 &#40;50&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;66&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n del prurito&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;60&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45 &#40;56&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;70&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n del dolor articular&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;16&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26 &#40;32&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;48&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Reducci&#243;n de la fatiga&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;25&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;42&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a del estado de &#225;nimo&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;70&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mejor&#237;a del bienestar general&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;57&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;46&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;72&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708764.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0060">Se muestra recuento y porcentaje para la respuesta &#171;de acuerdo&#187; o &#171;totalmente de acuerdo&#187; a la pregunta para el dermat&#243;logo &#171;&#191;De qu&#233; manera cree que apremilast ha ayudado en el tratamiento de la psoriasis de este paciente&#63;&#187; y a la pregunta para el paciente &#171;&#191;De qu&#233; manera cree que apremilast ha ayudado en el tratamiento de su psoriasis&#63;&#187;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0055"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0065">Por ejemplo cuero cabelludo&#44; manos&#44; plantas de los pies&#44; u&#241;as y&#47;o genitales&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Niveles de satisfacci&#243;n de dermat&#243;logos y pacientes respecto al efecto del tratamiento sobre los s&#237;ntomas &#40;datos de los cuestionarios espec&#237;ficos&#41;</p>"
        ]
      ]
      9 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabla 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acontecimientos adversos &#40;AAs&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Poblaci&#243;n de seguridad &#40;n &#61; 80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con alg&#250;n AA&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45 &#40;56&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con AA graves&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes con AA que llevan a la retirada de la medicaci&#243;n&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;22&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">AA que suceden en &#8805;5&#37; de los pacientes&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N&#225;useas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;18&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>V&#243;mito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cefalea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">AA que llevan a la retirada de la medicaci&#243;n &#40;&#8805;5&#37; de los pacientes&#41;&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">&#167;</span></a></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>N&#225;useas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>V&#243;mito&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;5&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cefalea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;5&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pacientes con p&#233;rdida de peso&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;27&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cambios en el peso&#44; media &#40;DE&#41;&#44; kg<a class="elsevierStyleCrossRef" href="#tblfn0065"><span class="elsevierStyleSup">&#8225;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-5&#44;3 &#40;4&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cambios en el peso&#44; media &#40;DE&#41;&#44; kg<a class="elsevierStyleCrossRef" href="#tblfn0070"><span class="elsevierStyleSup">&#8224;</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;2 &#40;2&#44;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2708762.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0060"
              "etiqueta" => "&#167;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0070">Se muestra el n&#250;mero de pacientes&#44; el porcentaje es en base al n&#250;mero total de pacientes&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0065"
              "etiqueta" => "&#8225;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0075">Para los pacientes que reportaron p&#233;rdida de peso&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0070"
              "etiqueta" => "&#8224;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0080">Para la totalidad de pacientes con datos disponibles del peso&#46;</p> <p class="elsevierStyleNotepara" id="npar0085">AA&#58; acontecimiento adverso&#59; DE&#58; desviaci&#243;n est&#225;ndar&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Seguridad con apremilast</p>"
        ]
      ]
      10 => array:5 [
        "identificador" => "fig0030"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 1075
            "Ancho" => 1333
            "Tamanyo" => 171831
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:19 [
            0 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "otezla-epar-product-information&#95;en&#46;pdf&#46; &#40;Consultado 23 Jul 2020&#41;&#46; https&#58;&#47;&#47;www&#46;ema&#46;europa&#46;eu&#47;en&#47;documents&#47;product-information&#47;otezla-epar-product-information&#95;en&#46;pdf"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Apremilast&#44; an oral phosphodiesterase 4 &#40;PDE4&#41; inhibitor&#44; in patients with moderate to severe plaque psoriasis&#58; Results of a phase III&#44; randomized&#44; controlled trial &#40;Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis &#91;ESTEEM&#93; 1&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Papp"
                            1 => "K&#46; Reich"
                            2 => "C&#46;L&#46; Leonardi"
                            3 => "L&#46; Kircik"
                            4 => "S&#46; Chimenti"
                            5 => "R&#46;G&#46;B&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2015.03.049"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "73"
                        "paginaInicial" => "37"
                        "paginaFinal" => "49"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26089047"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of apremilast&#44; an oral phosphodiesterase 4 inhibitor&#44; in patients with moderate-to-severe plaque psoriasis over 52&#160;weeks&#58; a phase III&#44; randomized controlled trial &#40;ESTEEM 2&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Paul"
                            1 => "J&#46; Cather"
                            2 => "M&#46; Gooderham"
                            3 => "Y&#46; Poulin"
                            4 => "U&#46; Mrowietz"
                            5 => "C&#46; Ferrandiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14164"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "173"
                        "paginaInicial" => "1387"
                        "paginaFinal" => "1399"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26357944"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy and safety of apremilast&#44; etanercept and placebo in patients with moderate-to-severe plaque psoriasis&#58; 52-week results from a phase IIIb&#44; randomized&#44; placebo-controlled trial &#40;LIBERATE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "M&#46; Gooderham"
                            2 => "L&#46; Green"
                            3 => "A&#46; Bewley"
                            4 => "Z&#46; Zhang"
                            5 => "I&#46; Khanskaya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14015"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "31"
                        "paginaInicial" => "507"
                        "paginaFinal" => "517"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27768242"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis&#58; 52-Week Results of UNVEIL"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Stein Gold"
                            1 => "J&#46; Bagel"
                            2 => "M&#46; Lebwohl"
                            3 => "J&#46;M&#46; Jackson"
                            4 => "R&#46; Chen"
                            5 => "J&#46; Goncalves"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "17"
                        "paginaInicial" => "221"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29462231"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characteristics and Outcomes of Patients Treated With Apremilast in the Real World&#58; Results From the APPRECIATE Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "C&#46;E&#46; Kleyn"
                            2 => "C&#46; Conrad"
                            3 => "P&#46;G&#46; Sator"
                            4 => "M&#46; St&#229;hle"
                            5 => "K&#46; Eyerich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16431"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "123"
                        "paginaFinal" => "134"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32279378"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46;J&#46;G&#46; Chalmers"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2014.09.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin&#46;"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "57"
                        "paginaFinal" => "71"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25412783"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dermatology Life Quality Index &#40;DLQI&#41;&#8212;a simple practical measure for routine clinical use"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;Y&#46; Finlay"
                            1 => "G&#46;K&#46; Khan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2230.1994.tb01167.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "1994"
                        "volumen" => "19"
                        "paginaInicial" => "210"
                        "paginaFinal" => "216"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8033378"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46; Feuerhahn"
                            1 => "C&#46; Blome"
                            2 => "M&#46; Radtke"
                            3 => "M&#46; Augustin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00403-012-1256-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol Res&#46;"
                        "fecha" => "2012"
                        "volumen" => "304"
                        "paginaInicial" => "433"
                        "paginaFinal" => "441"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22722916"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hierarchical construct validity of the treatment satisfaction questionnaire for medication &#40;TSQM version II&#41; among outpatient pharmacy consumers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;J&#46; Atkinson"
                            1 => "R&#46; Kumar"
                            2 => "J&#46;C&#46; Cappelleri"
                            3 => "S&#46;L&#46; Hass"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1524-4733.2005.00066.x"
                      "Revista" => array:5 [
                        "tituloSerie" => "Value Health J Int Soc Pharmacoeconomics Outcomes Res&#46;"
                        "fecha" => "2005"
                        "volumen" => "8 &#40;Suppl 1&#41;"
                        "paginaInicial" => "S9"
                        "paginaFinal" => "S24"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Armstrong"
                            1 => "E&#46; Levi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Drugs Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "16"
                        "paginaInicial" => "1240"
                        "paginaFinal" => "1245"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Apremilast in psoriasis - a prospective real-world study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Vujic"
                            1 => "R&#46; Herman"
                            2 => "M&#46; Sanlorenzo"
                            3 => "C&#46; Posch"
                            4 => "B&#46; Monshi"
                            5 => "K&#46; Rappersberger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14598"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "254"
                        "paginaFinal" => "259"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28925560"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice&#58; A Canadian multicenter retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Ighani"
                            1 => "J&#46;R&#46; Georgakopoulos"
                            2 => "S&#46; Walsh"
                            3 => "N&#46;H&#46; Shear"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.060"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "623"
                        "paginaFinal" => "626"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28989112"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-World Experience With Apremilast in Treating Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;N&#46; Mayba"
                            1 => "M&#46;J&#46; Gooderham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1203475416676030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Cutan Med Surg&#46;"
                        "fecha" => "2017"
                        "volumen" => "21"
                        "paginaInicial" => "145"
                        "paginaFinal" => "151"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27846617"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Papadavid"
                            1 => "N&#46; Rompoti"
                            2 => "K&#46; Theodoropoulos"
                            3 => "G&#46; Kokkalis"
                            4 => "D&#46; Rigopoulos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.14832"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "1173"
                        "paginaFinal" => "1179"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Real-world effectiveness and safety of apremilast in psoriasis at 52&#160;weeks&#58; a retrospective&#44; observational&#44; multicentre study by the Spanish Psoriasis Group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Del Alc&#225;zar"
                            1 => "J&#46;A&#46; Su&#225;rez-P&#233;rez"
                            2 => "S&#46; Armesto"
                            3 => "R&#46; Rivera"
                            4 => "E&#46; Herrera-Acosta"
                            5 => "P&#46; Herranz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16439"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2020"
                        "volumen" => "34"
                        "paginaInicial" => "2821"
                        "paginaFinal" => "2829"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32271966"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig Sanz"
                            1 => "S&#46; Armesto"
                            2 => "E&#46; Montesinos"
                            3 => "A&#46;M&#46; Morales Callaghan"
                            4 => "R&#46; Rivera"
                            5 => "F&#46;J&#46; Latasa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "APPROPRIATE&#58; Estudio observacional prospectivo sobre los beneficios de apremilast en pacientes con psoriasis en placa tras otros tratamientos sist&#233;micos en condiciones de pr&#225;ctica cl&#237;nica en Espa&#241;a In&#58; Congreso virtual AEDV"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials&#58; A multicenter retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Ighani"
                            1 => "J&#46;R&#46; Georgakopoulos"
                            2 => "N&#46;H&#46; Shear"
                            3 => "S&#46; Walsh"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.067"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "801"
                        "paginaFinal" => "803"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29017843"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46;B&#46; Lee"
                            1 => "M&#46; Amin"
                            2 => "A&#46; Egeberg"
                            3 => "J&#46;J&#46; Wu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15061"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "e393"
                        "paginaFinal" => "e394"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29730885"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack558531"
        "titulo" => "Agradecimientos"
        "texto" => "<p id="par0230" class="elsevierStylePara elsevierViewall">Los autores quieren agradecer a todos los investigadores&#44; coordinadores y al personal de los centros participantes&#44; as&#237; como a los pacientes por su participaci&#243;n en este estudio&#46; El soporte en la redacci&#243;n m&#233;dica fue proporcionado por Irene Mansilla&#44; MSc&#44; de TFS S&#46;L&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021002027/v1_202110020514/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6163"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011200000009/v1_202110020514/S0001731021002027/v1_202110020514/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021002027?idApp=UINPBA000044"
]
Article information
ISSN: 00017310
Original language: Spanish
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 13 8 21
2024 October 120 51 171
2024 September 108 24 132
2024 August 126 66 192
2024 July 112 35 147
2024 June 121 40 161
2024 May 125 36 161
2024 April 109 50 159
2024 March 101 36 137
2024 February 143 40 183
2024 January 117 43 160
2023 December 105 17 122
2023 November 106 37 143
2023 October 108 40 148
2023 September 105 27 132
2023 August 74 17 91
2023 July 77 31 108
2023 June 67 31 98
2023 May 102 27 129
2023 April 71 26 97
2023 March 110 36 146
2023 February 90 32 122
2023 January 49 33 82
2022 December 79 45 124
2022 November 125 62 187
2022 October 107 67 174
2022 September 78 50 128
2022 August 101 70 171
2022 July 95 59 154
2022 June 131 75 206
2022 May 109 54 163
2022 April 71 52 123
2022 March 103 89 192
2022 February 66 59 125
2022 January 70 57 127
2021 December 67 56 123
2021 November 108 77 185
2021 October 190 103 293
2021 September 86 45 131
2021 August 92 43 135
2021 July 94 60 154
2021 June 98 133 231
2021 May 7 18 25
Show all

Follow this link to access the full text of the article

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?